Endocrinology and Metabolism

Original Article

Impact of Carbohydrate Intake Fluctuations on Glucose Profiles: Insights from Continuous Glucose Monitoring-Based Patient Clustering: Hyun Ah Kim, Kyung Hee Kim, Young Lee, Yoon-Ju Song, Joon Ho Moon, Sung Hee Choi, Tae Jung Oh; Received June 4, 2025 Accepted September 15, 2025 Published online December 12, 2025; DOI: https://doi.org/10.3803/EnM.2025.2486 [Epub ahead of print]

386 View
27 Download

Abstract PDF PubReader ePub: Background
Continuous glucose monitoring (CGM) is widely applied in daily glucose management. However, its potential to categorize individuals based on glucose profiles is not fully established. This study employed CGM-based patient clustering and examined nutritional factors influencing glucose patterns.
Methods
This prospective observational study enrolled 34 individuals with diabetes. Retrospective professional CGM was conducted over 7 days, during which food intake was recorded. K-means clustering was performed using CGM-derived coefficient of variation (CV) and time in range. Macronutrient intake and its fluctuations were compared across clusters.
Results
Participants were grouped into cluster 1 (well-controlled), cluster 2 (highest CV), and cluster 3 (highest mean glucose). Baseline clinical characteristics, daily energy intake (kcal), and macronutrient intake did not differ significantly among clusters. However, carbohydrate intake fluctuations were greater in cluster 3 (CV 41.0%±32.1%, standard deviation [SD] 502.1±363.4 kcal) than in cluster 1 (CV 21.9%±9.0%, SD 260.2±94.1 kcal) and cluster 2 (CV 19.2%±9.1%, SD 250.2±126.1 kcal) (P=0.123 for CV; P=0.024 for SD). The SD (kcal) of carbohydrate intake was positively correlated with mean glucose levels (rho=0.88, P=0.023).
Conclusion
CGM enables categorization of individuals based on glucose profiles, and higher carbohydrate intake fluctuations are associated with poorer glycemic control. Personalized dietary strategies, particularly stabilizing carbohydrate intake, may support better glucose management in individuals with high mean glucose and low CV.

Review Articles

Thyroid
Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma: Chan Kwon Jung, Agnes Stephanie Harahap; Endocrinol Metab. 2025;40(6):830-850. Published online December 11, 2025; DOI: https://doi.org/10.3803/EnM.2025.2725

861 View
68 Download

Abstract PDF PubReader ePub: High-grade differentiated thyroid carcinoma (HGDTC) is a recently codified entity in the 2022 World Health Organization Classification of Endocrine Tumors, defined by a mitotic count of ≥5 mitoses per 2 mm² and/or tumor necrosis in a carcinoma that retains papillary, follicular, or oncocytic differentiation without anaplastic morphology. Although uncommon, HGDTC presents significant diagnostic and therapeutic challenges. This review summarizes current evidence regarding histopathologic recognition, molecular features, prognostic determinants, and evolving treatment paradigms. Particular attention is given to pattern-specific pitfalls such as high-grade papillary thyroid carcinoma, the diffuse sclerosing subtype, and the prognostic influence of the invasion phenotype (encapsulated versus infiltrative). Subcentimeter papillary carcinomas exhibiting increased mitotic activity alone should not be overinterpreted as HGDTC. An integrated, stepwise approach is proposed to enhance diagnostic reproducibility, refine risk stratification, and optimize multidisciplinary management in clinical practice.

Thyroid
The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline: Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Jeongmin Lee, Dong-Jun Lim, Chan Kwon Jung, Young Joo Park, on Behalf of the Korean Thyroid Association Clinical Guideline Committee; Endocrinol Metab. 2025;40(3):357-384. Published online June 24, 2025; DOI: https://doi.org/10.3803/EnM.2025.2465

6,175 View
202 Download
3 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

In 2024, the Korean Thyroid Association (KTA) introduced a revised Risk Stratification System (K-RSS) for differentiated thyroid cancer, building upon the modified RSS (M-RSS) proposed by the American Thyroid Association in 2015. The K-RSS emphasizes the cumulative impact of coexisting clinical and pathological features, acknowledging that multiple intermediate-risk factors collectively indicate a higher recurrence risk. Histologic classification follows the 2022 World Health Organization classification, consolidating encapsulated follicular-patterned thyroid carcinomas, including invasive encapsulated follicular variant papillary thyroid carcinoma, follicular thyroid carcinoma, and oncocytic carcinoma of the thyroid gland, and stratifying them by the extent of capsular and vascular invasion. High-grade thyroid carcinoma is newly included. Updated criteria for tumor size and extrathyroidal extension (ETE) represent another significant change. BRAF^V600E-mutated papillary thyroid carcinomas measuring 1 to 2 cm are now considered lower risk than previously classified in the M-RSS, while encapsulated follicular-patterned tumors larger than 4 cm are considered higher risk. Both minimal ETE and gross ETE confined to the strap muscles have been downgraded to low and intermediate risk, respectively. These changes are accompanied by updates regarding molecular profiling and surgical margin status. Collectively, these updates aim to minimize overtreatment in low-risk patients, while ensuring intensified management for those at higher risk.

Citations

Citations to this article as recorded by

Who Really Needs RAI Ablation Therapy for Low-to-Intermediate Risk Differentiated Thyroid Cancer? Insights from the IoN Trial
Young Joo Park
Clinical Thyroidology®.2025; 37(9): 323. CrossRef
From Classification to Personalization: Advances in Thyroid Cancer Risk Stratification Systems
Mijin Kim, Bo Hyun Kim
Endocrinology and Metabolism.2025; 40(5): 689. CrossRef
Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study
Mijin Kim, Eun Kyung Lee, Kyeong Jin Kim, Soo Myoung Shin, Jinsun Jang, Je Yoon Shin, Meihua Jin, Ja Seong Bae, Kwangsoon Kim, Won Gu Kim, Min Ji Jeon, Seung Heon Kang, Hee Kyung Kim, Jee Hee Yoon, Yea Eun Kang, Hwa Young Ahn, Young Joo Park, Bo Hyun Kim
Thyroid®.2025;[Epub] CrossRef
Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma
Chan Kwon Jung, Agnes Stephanie Harahap
Endocrinology and Metabolism.2025; 40(6): 830. CrossRef

Original Articles

Thyroid
Association of the Preoperative Controlling Nutritional Status (CONUT) Score with Clinicopathological Characteristics in Patients with Papillary Thyroid Carcinoma: Doohwa Kim, Myungsoo Im, Soree Ryang, Mijin Kim, Yun Kyung Jeon, Sang Soo Kim, Bo Hyun Kim; Endocrinol Metab. 2024;39(6):856-863. Published online November 15, 2024; DOI: https://doi.org/10.3803/EnM.2024.2006

2,469 View
81 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The Controlling Nutritional Status (CONUT) score is an immunonutritional test tool based on serum albumin, total cholesterol, and lymphocyte counts. It has been studied as a simple prognostic predictor for various carcinomas. This study aimed to investigate the association between preoperative CONUT scores and the clinicopathological characteristics in papillary thyroid carcinoma (PTC) patients.
Methods
This study included 2,403 PTC patients who underwent total thyroidectomy between 2012 and 2016 at a single tertiary medical center. The CONUT scores were calculated based on preoperative blood tests. The clinicopathological characteristics were retrospectively reviewed. The patients were categorized by the CONUT score (relatively low, 0–2; relatively high, 3–5).
Results
Among the 2,997 PTC patients who underwent total thyroidectomy at Pusan National University Hospital between 2012 and 2016, those without preoperative blood test were excluded (n=149). Finally 2,403 patients were analyzed after excluding 439 patients taking lipid-lowering drugs and six patients without available T stage data after surgery. Based on the CONUT score, the relatively high score group had a lower body mass index (23.7±3.3 kg/m² vs. 21.9±2.9 kg/m², P<0.001), more advanced T stage (T stage 3/4, 5.9% vs. 11.4%, P=0.045), and higher extrathyroidal extension (2.1% vs. 7.6%, P=0.005).
Conclusion
Patients included in this large, single-center study all had a preoperative CONUT score of 0–5, but this study demonstrated that higher preoperative CONUT scores were significantly associated with advanced T stage and extrathyroidal extension. The CONUT score, which can be easily used in clinical practice, is thought to be helpful in predicting the aggressiveness of PTC.

Citations

Citations to this article as recorded by

Prognostic Impact of the Pretreatment Controlling Nutritional Status (CONUT) Score in Anaplastic Thyroid Cancer: A Retrospective Cohort Study
Sun-Kyung Park, Nam Kyung Kim, Jun Sung Lee, Hyeok Jun Yun, Yong Sang Lee, Hye Sun Lee, Seok-Mo Kim, Young Song
Cancers.2025; 17(20): 3344. CrossRef
Machine learning-based prediction of clinical outcomes in cervical cancer using routine hematological indices: development and web implementation
Gaigai Bai, Fanghua Chen, Junjun Qiu, Keqin Hua
Frontiers in Oncology.2025;[Epub] CrossRef

Adrenal gland
The Modified S-GRAS Scoring System for Prognosis in Korean with Adrenocortical Carcinoma: Sun Kyung Baek, Seung Hun Lee, Seung Shin Park, Chang Ho Ahn, Sung Hye Kong, Won Woong Kim, Yu-Mi Lee, Su Jin Kim, Dong Eun Song, Tae-Yon Sung, Kyu Eun Lee, Jung Hee Kim, Kyeong Cheon Jung, Jung-Min Koh; Endocrinol Metab. 2024;39(5):803-812. Published online September 25, 2024; DOI: https://doi.org/10.3803/EnM.2024.2086

3,144 View
86 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Adrenocortical carcinomas (ACCs) are rare tumors with aggressive but varied prognosis. Stage, Grade, Resection status, Age, Symptoms (S-GRAS) score, based on clinical and pathological factors, was found to best stratify the prognosis of European ACC patients. This study assessed the prognostic performance of modified S-GRAS (mS-GRAS) scores including modified grade (mG) by integrating mitotic counts into the Ki67 index (original grade), in Korean ACC patients.
Methods
Patients who underwent surgery for ACC between January 1996 and December 2022 at three medical centers in Korea were retrospectively analyzed. mS-GRAS scores were calculated based on tumor stage, mG (Ki67 index or mitotic counts), resection status, age, and symptoms. Patients were divided into four groups (0–1, 2–3, 4–5, and 6–9 points) based on total mS-GRAS score. The associations of each variable and mS-GRAS score with recurrence and survival were evaluated using Cox regression analysis, Harrell’s concordance index (C-index), and the Kaplan–Meier method.
Results
Data on mS-GRAS components were available for 114 of the 153 patients who underwent surgery for ACC. These 114 patients had recurrence and death rates of 61.4% and 48.2%, respectively. mS-GRAS score was a significantly better predictor of recurrence (C-index=0.829) and death (C-index=0.747) than each component (P<0.05), except for resection status. mS-GRAS scores correlated with shorter progression-free survival (P=8.34E-24) and overall survival (P=2.72E-13).
Conclusion
mS-GRAS scores showed better prognostic performance than tumor stage and grade in Asian patients who underwent surgery for ACC.

Citations

Citations to this article as recorded by

External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy
Paula Jimenez-Fonseca, Cristina Álvarez-Escola, Inmaculada Ballester Navarro, Jorge Hernando Cubero, Laura González Fernández, Miguel Ángel Mangas Cruz, Clara Iglesias, Jesús García-Donas, María José Picón, Miguel Paja, Lorena González Batanero, Lourdes G
European Journal of Endocrinology.2025; 193(2): 320. CrossRef

Thyroid
Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis: Ji Young Kim, Jae Kyung Myung, Soyun Kim, Kyung Tae, Yun Young Choi, Soo Jin Lee; Endocrinol Metab. 2024;39(4):590-602. Published online June 27, 2024; DOI: https://doi.org/10.3803/EnM.2024.1927

11,156 View
264 Download
5 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Poorly differentiated thyroid carcinoma (PDTC) accounts for a small portion of thyroid carcinomas but contributes to a significant proportion of thyroid carcinoma-associated deaths. The clinicopathological prognostic factors and clinical outcomes of PDTC remain unclear. We aimed to evaluate the clinical outcomes of patients with PDTC after curative treatment.
Methods
A comprehensive search was performed up to September 2023. We included studies investigating treatment outcomes in patients with PDTC who underwent initial surgery. The 5-year disease-free survival (DFS) and overall survival (OS) were extracted. In this meta-analysis, the enrolled PDTC histological criteria included 3rd, 4th, and 5th World Health Organization (WHO) and Memorial Sloan Kettering Cancer Center (MSKCC) classification. A random-effects model was used for the pooled proportion analysis. Meta-regression analysis was conducted to evaluate the prognostic factors.
Results
Twenty retrospective studies published between 2007 and 2023, including 1,294 patients, met all inclusion criteria. Studies that diagnosed PDTC based on various histological criteria including 3rd WHO (n=5), 4th WHO (n=12), 5th WHO (n=2), and MSKCC (n=1) were included. Overall, 5-year DFS and 5-year OS were 49.4% (95% confidence interval [CI], 42.3 to 56.4) and 73.8% (95% CI, 66.5 to 79.9), with moderate heterogeneity of 58% and 55%, respectively. In meta-regression analysis, extrathyroidal extension (ETE) was a prognostic factor for OS.
Conclusion
The meta-analysis of DFS and OS in patients with PDTC show the moderate heterogeneity with a variety of histological criteria. ETE appears to have a significant impact on OS, regardless of histological criteria.

Citations

Citations to this article as recorded by

Differentiated high-grade thyroid carcinoma (DHGTC): clinicopathological analysis of a new entity in a chilean center
Marlín Solórzano, Ignacio Fuentes, José Miguel González, Nicole Lustig, Lorena Mosso, Joel Falcón, Catalina Ruiz, Joaquín Viñambres, Rodolfo Cabello, Hernán González, Pablo H Montero, Francisco Cruz, Rodrigo Jaimovich, Juan Carlos Quintana, Antonieta Sola
Endocrine.2026;[Epub] CrossRef
Poorly differentiated thyroid carcinoma in identical twins: a report of two cases and review of the literature
Amal El Masri, Celine El Moughrabi, Anas El Zouhbi, Anthony Shebly, Hala Kassouf, Mustafa Natout, Yusef Hazimeh, Mustapha El Lakis
Thyroid Research.2026;[Epub] CrossRef
Multilayered Insights into Poorly Differentiated, BRAFV600E-Positive, Thyroid Carcinoma in a Rapidly Developing Goiter with Retrosternal Extension: From En “Y” Cervicotomy to SPECT/CT-Positive Lung Metastases
Oana-Claudia Sima, Anca-Pati Cucu, Dana Terzea, Claudiu Nistor, Florina Vasilescu, Lucian-George Eftimie, Mihai-Lucian Ciobica, Mihai Costachescu, Mara Carsote
Diagnostics.2025; 15(16): 2049. CrossRef
GDF15 is associated with thyroid cancer progression and may modulate thyroid cancer cell senescence in a p53-dependent manner
Jingyu Ma, Zishuo Liu, Rui Hua, Changyuan Ding, Zhenpeng Yang, Weili Liang, Bin Lv
Frontiers in Endocrinology.2025;[Epub] CrossRef
Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis)
Mihai Costachescu, Nina Ionovici , Dana Cristina Terzea , Florina Vasilescu , Lucian-George Eftimie , Alexandra-Ioana Trandafir , Ana-Maria Gheorghe , Oana-Claudia Sima , Claudiu Nistor , Mara Carsote
Romanian Journal of Morphology and Embryology.2025; 66(3): 431. CrossRef
Aggressive Types of Malignant Thyroid Neoplasms
Maria Boudina, Eleana Zisimopoulou, Persefoni Xirou, Alexandra Chrisoulidou
Journal of Clinical Medicine.2024; 13(20): 6119. CrossRef

Thyroid
Clinical Characteristics and Prognosis of Coexisting Thyroid Cancer in Patients with Graves’ Disease: A Retrospective Multicenter Study: Jee Hee Yoon, Meihua Jin, Mijin Kim, A Ram Hong, Hee Kyung Kim, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Ho-Cheol Kang; Endocrinol Metab. 2021;36(6):1268-1276. Published online November 26, 2021; DOI: https://doi.org/10.3803/EnM.2021.1227

9,112 View
226 Download
17 Web of Science
17 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The association between Graves’ disease (GD) and co-existing thyroid cancer is still controversial and most of the previously reported data have been based on surgically treated GD patients. This study investigated the clinicopathological findings and prognosis of concomitant thyroid cancer in GD patients in the era of widespread application of ultrasonography.
Methods
Data of GD patients who underwent thyroidectomy for thyroid cancer between 2010 and 2019 in three tertiary hospitals in South Korea (Asan Medical Center, Chonnam National University Hwasun Hospital, and Pusan National University Hospital) were collected and analyzed retrospectively. In the subgroup analysis, aggressiveness and clinical outcomes of thyroid cancer were compared nodular GD and non-nodular GD groups according to the presence or absence of the thyroid nodules other than thyroid cancer (index nodules).
Results
Of the 15,159 GD patients treated at the hospitals during the study period, 262 (1.7%) underwent thyroidectomy for coexisting thyroid cancer. Eleven patients (4.2%) were diagnosed with occult thyroid cancer and 182 patients (69.5%) had microcarcinomas. No differences in thyroid cancer aggressiveness, ultrasonographic findings, or prognosis were observed between the nodular GD and non-nodular GD groups except the cancer subtype. In the multivariate analysis, only lymph node (LN) metastasis was an independent prognostic factor for recurrent/persistent disease of thyroid cancer arising in GD (P=0.020).
Conclusion
The prevalence of concomitant thyroid cancer in GD patients was considerably lower than in previous reports. The clinical outcomes of thyroid cancer in GD patients were also excellent but, more cautious follow-up is necessary for patients with LN metastasis in the same way as for thyroid cancer in non-GD patients.

Citations

Citations to this article as recorded by

Incidental Thyroid Cancer in Patients With Graves’ Disease: Not as Rare as We Previously Believed
Shaidy Moronta, Lauren Slattery, Rongzhi Wang, Fiemu Nwariaku, Jessica Liu McMullin
Journal of Surgical Research.2025; 308: 122. CrossRef
Preoperative serum lipids as novel predictors for concomitant thyroid carcinoma in Graves’ disease
Xingxing Gao, Mi Liu, Yijun Wu
PeerJ.2025; 13: e19915. CrossRef
Clinicopathologic predictors of incidental thyroid cancer in Graves’ disease: a single-center retrospective cohort study
Wei Huang, Wei-Hsin Chen
Updates in Surgery.2025;[Epub] CrossRef
Comparison of Surgical Outcomes of Transoral Versus Open Thyroidectomy for Graves Disease
Suo-Hsien Wang, Wu-Po Chao, Ta-You Lo, Soh-Ching Ng, Yu-Hsien Chen
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 150. CrossRef
Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer
Anupam Kotwal, Krysten Vance, Kemal Hajric, Ana Yuil-Valdes, Benjamin Swanson, Ernesto Martinez Duarte, Oleg Shats, Michael Hollingsworth, Hamid Band, Whitney Goldner
Thyroid®.2024; 34(8): 999. CrossRef
The Role of Risk Factors for the Progression of Patients with T1b-T2 Papillary Thyroid Carcinoma (PC) during Long-Term Follow-Up
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Antonio Mura, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
Journal of Clinical Medicine.2024; 13(18): 5373. CrossRef
Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases
Hanxing Sun, Hui Tong, Xiaohui Shen, Haoji Gao, Jie Kuang, Xi Chen, Qinyu Li, Weihua Qiu, Zhuoran Liu, Jiqi Yan
Journal of Clinical Medicine.2023; 12(4): 1308. CrossRef
Cancer and Mortality Risks of Graves’ Disease in South Korea Based on National Data from 2010 to 2019
Young Ju Choi, Kyungdo Han, Won Kyoung Cho, Min Ho Jung, Byung-Kyu Suh
Clinical Epidemiology.2023; Volume 15: 535. CrossRef
Risk and Prognosis of Thyroid Cancer in Patients with Graves’ Disease: An Umbrella Review
Marco Palella, Francesca Maria Giustolisi, Adriana Modica Fiascaro, Martina Fichera, Antonella Palmieri, Rossella Cannarella, Aldo E. Calogero, Margherita Ferrante, Maria Fiore
Cancers.2023; 15(10): 2724. CrossRef
Characteristics, staging and outcomes of differentiated thyroid cancer in patients with and without Graves’ disease
Chaitra Gopinath, Hanna Crow, Sujata Panthi, Leonidas Bantis, Kenneth D. Burman, Chitra Choudhary
Journal of Clinical & Translational Endocrinology.2023; 33: 100321. CrossRef
Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study
Hwa Young Ahn, Sun Wook Cho, Mi Young Lee, Young Joo Park, Bon Seok Koo, Hang-Seok Chang, Ka Hee Yi
Endocrinology and Metabolism.2023; 38(4): 436. CrossRef
Hashimoto’s Thyroiditis and Papillary Thyroid Carcinoma: A Follow-Up Study in Patients with Absence of Aggressive Risk Factors at the Surgery of the Primary Tumor
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
Diagnostics.2023; 13(19): 3068. CrossRef
Table of Contents

Clinical Thyroidology.2022; 34(2): 48. CrossRef
Predisposition to and Prognosis of Thyroid Cancer May Not Be Affected by Graves’ Disease, But Some Questions Still Remain
Yanrui Huang, Haixia Guan
Clinical Thyroidology.2022; 34(2): 59. CrossRef
A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves’ Disease
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Maria Rondini, Angela Spanu, Giuseppe Madeddu
Diagnostics.2022; 12(11): 2801. CrossRef
An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
Thyroid Research and Practice.2022; 19(1): 47. CrossRef
An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
Thyroid Research and Practice.2021; 18(3): 129. CrossRef

Thyroid
Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea: Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim; Endocrinol Metab. 2021;36(5):1078-1085. Published online October 28, 2021; DOI: https://doi.org/10.3803/EnM.2021.1151

7,534 View
130 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Hürthle cell carcinoma (HCC), a type of thyroid carcinoma, is rare in South Korea, and few studies have investigated its prognosis.
Methods
This long-term multicenter retrospective cohort study evaluated the clinicopathological features and clinical outcomes in patients with HCC who underwent thyroid surgery between 1996 and 2009.
Results
The mean age of the 97 patients included in the study was 50.3 years, and 26.8% were male. The mean size of the primary tumor was 3.2±1.8 cm, and three (3.1%) patients had distant metastasis at initial diagnosis. Ultrasonographic findings were available for 73 patients; the number of nodules with low-, intermediate-, and high suspicion was 28 (38.4%), 27 (37.0%), and 18 (24.7%), respectively, based on the Korean-Thyroid Imaging Reporting and Data System. Preoperatively, follicular neoplasm (FN) or suspicion for FN accounted for 65.2% of the cases according to the Bethesda category, and 13% had malignancy or suspicious for malignancy. During a median follow-up of 8.5 years, eight (8.2%) patients had persistent/recurrent disease, and none died of HCC. Older age, gross extrathyroidal extension (ETE), and widely invasive types of tumors were significantly associated with distant metastasis (all P<0.01). Gross ETE (hazard ratio [HR], 27.7; 95% confidence interval [CI], 2.2 to 346.4; P=0.01) and widely invasive classification (HR, 6.5; 95% CI, 1.1 to 39.4; P=0.04) were independent risk factors for poor disease-free survival (DFS).
Conclusion
The long-term prognosis of HCC is relatively favorable in South Korea from this study, although this is not a nation-wide data, and gross ETE and widely invasive cancer are significant prognostic factors for DFS. The diagnosis of HCC by ultrasonography and cytopathology remains challenging.

Citations

Citations to this article as recorded by

Prognostic impact of fibrosclerotic changes in non-papillary, non-anaplastic, follicular cell-derived thyroid carcinomas
Giulia Orlando, Giulia Capella, Giulia Vocino Trucco, Elena Vissio, Jasna Metovic, Francesca Maletta, Marco Volante, Mauro Papotti
Virchows Archiv.2025; 487(3): 701. CrossRef
Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study
Eunji Kim, Jun Hyun Park, Ji-Young Park, Sang-Woo Lee, Jin Hyang Jung
Annals of Surgical Treatment and Research.2025; 109(2): 105. CrossRef
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John
Thyroid®.2025; 35(8): 841. CrossRef
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
Lindsay A. Bischoff, Ian Ganly, Laura Fugazzola, Erin Buczek, William C. Faquin, Bryan R. Haugen, Bryan McIver, Caitlin P. McMullen, Kate Newbold, Daniel J. Rocke, Marika D. Russell, Mabel Ryder, Peter M. Sadow, Eric Sherman, Maisie Shindo, David C. Shonk
JAMA Otolaryngology–Head & Neck Surgery.2024; 150(3): 265. CrossRef
Oncocytic carcinoma of the thyroid: Conclusions from a 20‐year patient cohort
Nelson R. Gruszczynski, Shahzeb S. Hasan, Ana G. Brennan, Julian De La Chapa, Adithya S. Reddy, David N. Martin, Prem P. Batchala, Edward B. Stelow, Eric M. Dowling, Katherine L. Fedder, Jonathan C. Garneau, David C. Shonka
Head & Neck.2024; 46(8): 2042. CrossRef
Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report
Xiqian Wang, Yingao Liu, Lijie Chen, Jie Zhang, Ruoyu Jiang, Lei Zhang, Han Yan, Jie Zhang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Clinical Considerations of Oncocytic Thyroid Cancer: A Review
Soo Young Kim
Journal of Endocrine Surgery.2024; 24(3): 49. CrossRef
Mitochondrial Proteome Defined Molecular Pathological Characteristics of Oncocytic Thyroid Tumors
Lu Li, Likun Zhang, Wenhao Jiang, Zhiqiang Gui, Zhihong Wang, Hao Zhang, Yi He, Yi Zhu, Tiannan Guo, Haixia Guan, Zhiyan Liu, Yaoting Sun, Jianqing Gao
Endocrine Pathology.2024; 35(4): 442. CrossRef
Hurthle cell carcinoma: a rare variant of thyroid malignancy – a case report
Yuvraj Adhikari, Anupama Marasini, Nawaraj Adhikari, Laxman D. Paneru, Binit Upadhaya Regmi, Manita Raut
Annals of Medicine & Surgery.2023; 85(5): 1940. CrossRef
Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature
Costanza Chiapponi, Milan J.M. Hartmann, Matthias Schmidt, Michael Faust, Christiane J. Bruns, Anne M. Schultheis, Hakan Alakus
Frontiers in Endocrinology.2022;[Epub] CrossRef

Thyroid
Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study: Mijin Kim, Sun Wook Cho, Young Joo Park, Hwa Young Ahn, Hee Sung Kim, Yong Joon Suh, Dughyun Choi, Bu Kyung Kim, Go Eun Yang, Il-Seok Park, Ka Hee Yi, Chan Kwon Jung, Bo Hyun Kim; Endocrinol Metab. 2021;36(3):619-627. Published online June 10, 2021; DOI: https://doi.org/10.3803/EnM.2021.974

8,486 View
209 Download
8 Web of Science
8 Crossref

Abstract PDF PubReader ePub

Background
We aimed to evaluate the clinicopathological features and biological behaviors of Korean thyroid cancer patients with rare variants of papillary thyroid carcinoma (PTC) to address the ambiguity regarding the prognostic consequences of these variants.
Methods
We retrospectively reviewed the medical records of 5,496 patients who underwent thyroid surgery for PTC, between January and December 2012, in nine tertiary hospitals. Rare PTC variants included tall cell (TCV), columnar cell (CCV), diffuse sclerosing (DSV), cribriform-morular (CMV), solid (SV), hobnail, and Warthin-like variants. Recurrence-free survival (RFS) was defined as the time from the date of thyroidectomy until recurrence.
Results
Rare variants accounted for 1.1% (n=63) of the PTC patients; with 0.9% TCV, 0.02% CCV, 0.1% DSV, 0.1% CMV, and 0.1% SV. The mean age of patients and primary tumor size were 42.1±13.1 years and 1.3±0.9 cm, respectively. Extrathyroidal extension and cervical lymph node metastasis were observed in 38 (60.3%) and 37 (58.7%) patients, respectively. Ultrasonographic findings revealed typical malignant features in most cases. During a median follow-up of 7 years, 6.3% of patients experienced a locoregional recurrence. The 5-year RFS rates were 71.4% in patients with DSV or SV, 95.9% for TCV, or CCV, and 100% for other variants. DSV emerged an independent risk factor associated with shorter RFS.
Conclusion
In this multicenter Korean cohort, rare variants accounted for 1.1% of all PTC cases, with TCV being the most frequent subtype. DSV emerged as a significant prognostic factor for RFS.

Citations

Citations to this article as recorded by

Optimizing unsupervised feature engineering and classification pipelines for differentiated thyroid cancer recurrence prediction
Emmanuel Onah, Uche Jude Eze, Abdullahi Salahudeen Abdulraheem, Ugochukwu Gabriel Ezigbo, Kosisochi Chinwendu Amorha, Fidele Ntie-Kang
BMC Medical Informatics and Decision Making.2025;[Epub] CrossRef
The Role of p27kip1 in the Aggressiveness of Papillary Thyroid Carcinoma: A Clinicopathological Analysis
Wafaa K. Ibrahim, Khitam R. Al-khafaji
Journal of the Faculty of Medicine Baghdad.2025; 67(3): 351. CrossRef
Nomogram predicts cervical lymph node metastasis of pathological subtypes of papillary thyroid carcinoma
Ziyu Luo, Wenhan Li, Binliang Huo, Jianhui Li
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Do Histologically Aggressive Subtypes of Papillary Thyroid Microcarcinoma have Worse Clinical Outcome than Non-Aggressive Papillary Thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study
Sayid Shafi Zuhur, Hunkar Aggul, Ugur Avci, Selvinaz Erol, Mazhar Müslüm Tuna, Serhat Uysal, Gulhan Akbaba, Faruk Kilinç, Merve Catak, Sakin Tekin, Ogun Irem Bilen, Beyza Olcay Öztürk, Ecem Bilgehan Erden, Gulsah Elbuken, Halise Cinar Yavuz, Pinar Kadiogl
Hormone and Metabolic Research.2023; 55(05): 323. CrossRef
The Warthin-like variant of papillary thyroid carcinomas: a clinicopathologic analysis report of two cases
Xing Zhao, Yijia Zhang, Pengyu Hao, Mingzhen Zhao, Xingbin Shen
Oncologie.2023; 25(5): 581. CrossRef
A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes
Ayanthi Wijewardene, Anthony J. Gill, Matti Gild, Diana L. Learoyd, Anthony Robert Glover, Mark Sywak, Stan Sidhu, Paul Roach, Geoffrey Schembri, Jeremy Hoang, Bruce Robinson, Lyndal Tacon, Roderick Clifton-Bligh
Thyroid.2022;[Epub] CrossRef
Clinicopathological Implications of the BRAFV600E Mutation in Papillary Thyroid Carcinoma of Ukrainian Patients Exposed to the Chernobyl Radiation in Childhood: A Study for 30 Years After the Accident
Liudmyla Zurnadzhy, Tetiana Bogdanova, Tatiana I. Rogounovitch, Masahiro Ito, Mykola Tronko, Shunichi Yamashita, Norisato Mitsutake, Michael Bolgov, Serhii Chernyshov, Sergii Masiuk, Vladimir A. Saenko
Frontiers in Medicine.2022;[Epub] CrossRef

Clinical Study
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer: Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim; Endocrinol Metab. 2021;36(1):96-105. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.819

9,729 View
214 Download
25 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Several cancers show increased levels of lactate dehydrogenase A (LDHA), which are associated with cancer progression. However, it remains unclear whether LDHA levels are associated with papillary thyroid cancer (PTC) aggressiveness or with the presence of the PTC prognostic marker, the BRAFV^600E mutation. This study aimed to evaluate the potential of LDHA as a PTC prognostic marker.
Methods
LDHA expression was examined in 83 PTC tissue specimens by immunohistochemistry. Human thyroid cell lines were genetically manipulated to overexpress BRAFV^600E or were treated with a BRAF-specific short hairpin RNA (shBRAF), whose effects on LDHA expression were evaluated by Western blotting. Data from 465 PTC patients were obtained from The Cancer Genome Atlas (TCGA) database and analyzed to validate the in vitro results.
Results
LDHA was aberrantly overexpressed in PTC. Intense immunostaining for LDHA was observed in PTC specimens carrying mutated BRAF, whereas the intensity was less in wild-type BRAF samples. Overexpression of BRAFV^600E resulted in LDHA upregulation, whereas treatment with shBRAF downregulated LDHA in human thyroid cell lines. Furthermore, LDHA mRNA expression was significantly elevated and associated with BRAFV^600E expression in thyroid cancer tissues from TCGA database. Additionally, LDHA overexpression was found to be correlated with aggressive clinical features of PTC, such as lymph node metastases and advanced tumor stages.
Conclusion
LDHA overexpression is associated with the BRAFV^600E mutation and an aggressive PTC behavior. Therefore, LDHA may serve as a biomarker and therapeutic target in PTC.

Citations

Citations to this article as recorded by

Emerging Potential of Metabolomics in Thyroid Cancer—A Comprehensive Review
Sonam Kumari, Andrew Makarewicz, Joanna Klubo-Gwiezdzinska
Cancers.2025; 17(6): 1017. CrossRef
The Influence of Glycolytic Enzyme Expression on the Aggressiveness of Papillary Thyroid Carcinoma Using TCGA Data
Won Woong Kim, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung
Journal of Endocrine Surgery.2025; 25(1): 13. CrossRef
Emerging Mechanisms of Lactate Regulation of Biological Processes
Emma C. Fink, Edward T. Chouchani
Annual Review of Cancer Biology .2025; 9(1): 307. CrossRef
The effect of glycolytic enzyme expression and thyroiditis on the aggressiveness of papillary thyroid carcinoma: a retrospective cohort study
Won Woong Kim, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung
Annals of Surgical Treatment and Research.2025; 109(3): 169. CrossRef
Application of multimodal integration to develop preoperative diagnostic models for borderline and malignant ovarian tumors
Atsushi Kunishima, Daiki Inaba, Shohei Iyoshi, Yoshiki Ikeda, Mayuko Goto, Reina Muramatsu, Mizuki Hashimoto, Kosuke Yoshida, Kazumasa Mogi, Masato Yoshihara, Yukari Nagao, Satoshi Tamauchi, Akira Yokoi, Nobuhisa Yoshikawa, Kaoru Niimi, Norihiro Koizumi,
Scientific Reports.2025;[Epub] CrossRef
DriverSub-SVM: a machine learning approach for cancer subtype classification by integrating patient-specific and global driver genes
Junrong Song, Yuanli Gong, Zhiming Song, Xinggui Xu, Kun Qian, Yingbo Liu
BMC Bioinformatics.2025;[Epub] CrossRef
Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks
Ning Qu, Di Chen, Ben Ma, Lijun Zhang, Qiuping Wang, Yuting Wang, Hongping Wang, Zhaoxian Ni, Wen Wang, Tian Liao, Jun Xiang, Yulong Wang, Shi Jin, Dixin Xue, Weili Wu, Yu Wang, Qinghai Ji, Hui He, Hai-long Piao, Rongliang Shi
Nature Communications.2024;[Epub] CrossRef
Fibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer
Yongkang Ye, Fukan Yang, Zhanhao Gu, Wenxuan Li, Yinjiao Yuan, Shaoqian Liu, Le Zhou, Bo Han, Ruinian Zheng, Zhengguo Cao
Journal of Translational Medicine.2024;[Epub] CrossRef
Lactate Dehydrogenase A is Associated with Elevated FDG Metabolism, Radioiodine Non-avidity, and Poor Prognosis in Differentiated Thyroid Cancer
Tian Tian, Hongyuan Dai, Mengni Zhang, Minggang Su, Xueqin Chen, Rui Huang
Academic Radiology.2024; 31(10): 4011. CrossRef
Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
Cassie Pan, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J. Houlton, Brittany Barber, Zain H. Rizvi, Emily Marchiano, Neal Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Renato G. Martins, Jonathan R. Fromm, Cristina P. Rodriguez
Cancer Medicine.2023; 12(8): 9384. CrossRef
LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer
Liang Shi, Rui Duan, Zhenhua Sun, Qiong Jia, Wenyu Wu, Feng Wang, Jianjun Liu, Hao Zhang, Xue Xue
Cell Death & Differentiation.2023; 30(6): 1517. CrossRef
Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
Guochao Ye, Xiaomei Zhang, Mansheng Li, Zixiang Lin, Yongcan Xu, Haoru Dong, Jie Zhou, Jiaqi Zhang, Sheng Wang, Yunping Zhu, Xiaobo Yu, Xu Qian
BMC Cancer.2023;[Epub] CrossRef
Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola, Valerio Costa
British Journal of Cancer.2023; 129(2): 249. CrossRef
circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
Hongguo Xie, Xiaopeng Lu
Open Medicine.2023;[Epub] CrossRef
The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
Sai-li Duan, Min Wu, Zhe-Jia Zhang, Shi Chang
Journal of Translational Medicine.2023;[Epub] CrossRef
CENPE and LDHA were potential prognostic biomarkers of chromophobe renal cell carcinoma
Hui-feng Wu, Hao Liu, Zhe-wei Zhang, Ji-min Chen
European Journal of Medical Research.2023;[Epub] CrossRef
Classification for Staging and Managing Patients with Biopolymer-induced Human Adjuvant Disease
Jaime Eduardo Pachón Suárez, Marcela C. Salazar, Victor Z. Rizo
Plastic and Reconstructive Surgery - Global Open.2022; 10(2): e4137. CrossRef
Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
Endocrinology and Metabolism.2022; 37(1): 53. CrossRef
Drug delivery for metabolism targeted cancer immunotherapy
Taravat Khodaei, Sahil Inamdar, Abhirami P. Suresh, Abhinav P. Acharya
Advanced Drug Delivery Reviews.2022; 184: 114242. CrossRef
Sulfur quantum dot based fluorescence assay for lactate dehydrogenase activity detection
Shengnan Fan, Xiaoqing Li, Fanghui Ma, Minghui Yang, Juan Su, Xiang Chen
Journal of Photochemistry and Photobiology A: Chemistry.2022; 430: 113989. CrossRef
STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
Nan Huo, Rui Cong, Zhi-jia Sun, Wen-chao Li, Xiang Zhu, Chun-yuan Xue, Zhao Chen, Lu-yuan Ma, Zhong Chu, Yu-chen Han, Xiao-feng Kang, Song-hao Jia, Nan Du, Lei Kang, Xiao-jie Xu
Cell Death & Disease.2021;[Epub] CrossRef
80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53
Kun Yu, Hongjiang Lu, Yanhong Chen, Ying Xin, Zhuo Tan, Qiong Yang
Frontiers in Bioscience-Landmark.2021;[Epub] CrossRef

Review Article

Thyroid
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification: Yanhua Bai, Kennichi Kakudo, Chan Kwon Jung; Endocrinol Metab. 2020;35(4):696-715. Published online December 2, 2020; DOI: https://doi.org/10.3803/EnM.2020.807

28,492 View
1,538 Download
57 Web of Science
63 Crossref

Abstract PDF PubReader ePub

Advances in medical sciences and evidence-based medicine have led to momentous changes in classification and management of thyroid neoplasms. Much progress has been made toward avoiding overdiagnosis and overtreatment of thyroid cancers. The new 2017 World Health Organization (WHO) classification of thyroid neoplasms updated the diagnostic criteria and molecular and genetic characteristics reflecting the biology and behavior of the tumors, and newly introduced the category of borderline malignancy or uncertain malignant potential. Some neoplasms were subclassified, renamed, or redefined as a specific entity. This review introduces changes in the fourth edition WHO classification of thyroid tumors and updates the contemporary diagnosis and classification of thyroid tumors. We also discuss several challenges with the proposal of new diagnostic entities, since they have unique histopathologic and molecular features and clinical relevance.

Citations

Citations to this article as recorded by

Diagnostic impact of DNA methylation classification in adult and pediatric CNS tumors
Laetitia Lebrun, Nathalie Gilis, Manon Dausort, Chloé Gillard, Stefan Rusu, Karim Slimani, Olivier De Witte, Fabienne Escande, Florence Lefranc, Nicky D’Haene, Claude Alain Maurage, Isabelle Salmon
Scientific Reports.2025;[Epub] CrossRef
Effect of Genetic Ancestry on Phenotypes and Genotypes in Papillary Thyroid Cancer
Shun-Yu Chi, Yi-Chiung Hsu, Shih-Ping Cheng
OMICS: A Journal of Integrative Biology.2025; 29(4): 117. CrossRef
Cross-sectional Study to Determine the Diagnostic Accuracy of Cytokeratin-19 Immunomarker in the Diagnosis of Thyroid Malignancy with Histopathology as Gold Standard
Helena Laishram, Kunda Jagadale, Parineeta Shelke, Reena Bharadwaj
Nigerian Postgraduate Medical Journal.2025; 32(1): 61. CrossRef
Report of tall cell variant of papillary thyroid carcinoma in struma ovarii: An exceptional histology finding
Rita Yadav, Binita Kumari, Preeti Agarwal, Sonu Singh
Journal of Cancer Research and Therapeutics.2025; 21(1): 196. CrossRef
A cluster attention-based multiple instance learning network for enhancing histopathological image interpretation
Seokhwan Ko, Yu Ando, Moonsik Kim, Nora Jee-Young Park, Hyungsoo Han, Ji Young Park, Junghwan Cho
Computers in Biology and Medicine.2025; 193: 110353. CrossRef
High-Grade Neuroendocrine Tumor of the Gallbladder in a Young Female: A Rare Case Report and Literature Review
Vaibhav Sharma, Vishakha Maheshwari, Gurpreet Kaur Chawla
American Medical Journal Oncology.2025; : 139. CrossRef
Nodal Metastases in Oncocytic Carcinoma of the Thyroid Are Associated With Decreased Survival
Maksymillian J. Pilecki, Kelly M. Herremans, Daniel Neal, Michel S. Kabbash, Christiana M. Shaw, Ibrahim Nassour, Aditya S. Shirali
Journal of Surgical Research.2025; 314: 38. CrossRef
Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete response
Congcong Wang, Guohua Qin, Shuhui Wang, Yutian Li, Yaqi Lu, Xia Shen, Wei Sun, Jiao Li, Na Han, Chenghui Lu, Guoqiang Wang, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Xufu Wang, Yansong Lin, Xinfeng Liu
Future Oncology.2025; 21(22): 2911. CrossRef
Intrathyroid thymic carcinoma of the left thyroid lobe: A case report and literature review
Xinyao Wang, Xiaoxi Hao, Fangtong Teng, Hongyan Cui
Oral Oncology.2025; 169: 107658. CrossRef
Overdiagnosis of thyroid cancer in the United States: Improved estimates based on the SEER registries during 2000–2019
Minlu Zhang, Dongchen Xie, Yi Hu, Guoyou Qin, Wanghong Xu
International Journal of Cancer.2025;[Epub] CrossRef
Epidemiology, spectrum, and pathology of surgical thyroid resections in a metropolitan South African setting
M van der Merwe, AR Botha, D van der Byl
Journal of Endocrinology, Metabolism and Diabetes of South Africa.2025; 30(3): 67. CrossRef
Diagnostic Significance of Trophoblast Cell Surface Antigen-2 Expression in Benign and Malignant Thyroid Lesions
Antony Queen Jeneffar, Sivaraman Anitharani
Cureus.2025;[Epub] CrossRef
The frozen section trap of minimal atypia in synchronous medullary and papillary thyroid carcinoma: A case report
Yuanqi Chu, Ming Huang, Jiali Liu, Ru Wang, Xiaojun Xie
Medicine.2025; 104(44): e45628. CrossRef
A Case of Intrathyroid Thymic Carcinoma Coexisting with Papillary Thyroid Carcinoma
Sumin Yi, Yun Jeong Lee, Da Beom Heo, Bon Seok Koo
International Journal of Thyroidology.2025; 18(2): 185. CrossRef
Canine thyroid carcinomas: A review with emphasis on comparing the compact subtype of follicular thyroid carcinomas and medullary thyroid carcinomas
Jillian M. Athey, Miranda D. Vieson, Keith Bailey, Dan Rudmann, Wes A. Baumgartner, Kim A. Selting
Veterinary Pathology.2024; 61(1): 7. CrossRef
Accuracy and diagnostic performance of the Bethesda system for reporting thyroid cytopathology in a tertiary endocrine surgical referral center in Belgium
Sam Kinet, Hendrik Cornette, Klaas Van Den Heede, Nele Brusselaers, Sam Van Slycke
World Journal of Surgery.2024; 48(2): 386. CrossRef
Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
Xiaoquan Hong, Juxiang Li, Shaoyin Duan, Youkuang You
PeerJ.2024; 12: e16810. CrossRef
“Examining the link between tooth agenesis and papillary thyroid cancer: is there a risk factor?” Observational study
Željana Matošić, Luka Šimunović, Tomislav Jukić, Roko Granić, Senka Meštrović
Progress in Orthodontics.2024;[Epub] CrossRef
Research Progress of Tg and TgAb in Lymph Node Metastasis of Papillary Thyroid Carcinoma
月高
Advances in Clinical Medicine.2024; 14(03): 499. CrossRef
A patient with a rare co‐occurrence of papillary and follicular thyroid carcinomas
Vijayvardhan Kamalumpundi, Erin Meyers, Maisoon Torfah, Marcelo Lima de Gusmão Correia
Clinical Case Reports.2024;[Epub] CrossRef
Coexistence of intrathyroid thymic carcinoma and papillary thyroid carcinoma: a case report and literature review
Maryam Vajihinejad, Ali Ataei, Mohammad Pashmchi, Ali Aledavoud, Vahid Zand, Mohammad Ali Broomand, Mohammad Mohammadi, Niloofar Zare Reshkuiyeh
Frontiers in Oncology.2024;[Epub] CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 4. Pathological Diagnosis and Staging after Thyroidectomy 2024
Su-Jin Shin, Hee Young Na, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Young Joo Park, Young Shin Song, Eun Kyung Lee, Dong-Jun Lim, Yun Jae Chung, Chan Kwon Jung
International Journal of Thyroidology.2024; 17(1): 61. CrossRef
Clinical–Pathological Features of Thyroid Neoplasms in Young Patients Diagnosed in a Single Center
Aura Jurescu, Dan Brebu, Alexandra Corina Faur, Octavia Vita, Robert Barna, Adrian Vaduva, Oana Popa, Anca Muresan, Mihaela Iacob, Marioara Cornianu, Remus Cornea
Life.2024; 14(6): 696. CrossRef
Clinical, Pathological, and Immunohistochemical Predictors of Cause-Specific Mortality in Papillary Thyroid Cancer: Multivariate Analysis
M. A. Bakarev, A. A. Ivanov, E. L. Lushnikova
Bulletin of Experimental Biology and Medicine.2024; 177(3): 353. CrossRef
Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing
Alicia Belaiche, Grégoire B. Morand, Sena Turkdogan, Esther ShinHyun Kang, Véronique-Isabelle Forest, Marc P. Pusztaszeri, Michael P. Hier, Alex M. Mlynarek, Keith Richardson, Nader Sadeghi, Marco A. Mascarella, Sabrina D. Da Silva, Richard J. Payne
Current Oncology.2024; 31(10): 5919. CrossRef
Rare Columnar Cell Variant of Papillary Thyroid Carcinoma with Cervical Spine Metastasis: A Case Report
Jihye Yu, Goeun Yang, Ha Yeun Oh, Yoon Jong Ryu
Current Medical Imaging Reviews.2024;[Epub] CrossRef
Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma
Nguyen Thi Phuong, Mai Hong Son, Mai Huy Thong, Le Ngoc Ha
BMC Medical Imaging.2024;[Epub] CrossRef
Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study
Zheng Ding, Xuanbin Tao, Xianzhao Deng, Bomin Guo, Jie Kang, Bo Wu, Zhili Yang, Chunyan Chen, Ping Liu, Yingchao Zhang, Youben Fan, Zhiyan Liu
Journal of Cancer Research and Clinical Oncology.2023; 149(9): 6303. CrossRef
Intrathyroid thymic carcinoma: clinicopathological features and whole exome sequencing analysis
Jiayu Li, Run Xiang, Yunzhu Li, Qiong Liao, Yang Liu
Virchows Archiv.2023; 482(5): 813. CrossRef
Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma: A Case Report
Parth S Shirode, Anil D'cruz, Sataksi Chatterjee, Swayambhu Bhandarkar
Cureus.2023;[Epub] CrossRef
Histological Variants of Papillary Thyroid Cancer in Relation to Clinical and Morphological Parameters and Prognosis
A. A. Ivanov, M. A. Bakarev, E. L. Lushnikova
Bulletin of Experimental Biology and Medicine.2023; 174(5): 647. CrossRef
Molecular profile of follicular tumors of the thyroid gland
D. D. Dolidze, A. V. Shabunin, S. D. Сovantsev, Z. A. Bagateliya, Yu. N. Kobzev, D. L. Rotin, K. A. Mulaeva, M. V. Kovaleva
Head and Neck Tumors (HNT).2023; 13(1): 102. CrossRef
The predictive models based on multimodality ultrasonography for the differential diagnosis of thyroid nodules smaller than 10 mm
Gang Li, Sai Ma, Fan Zhang, Chao Jia, Long Liu, Feng Gao, Qiusheng Shi, Rong Wu, Lianfang Du, Fan Li
The British Journal of Radiology.2023;[Epub] CrossRef
The Warthin-like variant of papillary thyroid carcinomas: a clinicopathologic analysis report of two cases
Xing Zhao, Yijia Zhang, Pengyu Hao, Mingzhen Zhao, Xingbin Shen
Oncologie.2023; 25(5): 581. CrossRef
Giant Anaplastic Thyroid Carcinoma of Sarcomatoid Type with Obstructive Symptoms: A Case Report
Gustavo D Saenz-Poma, Shirley N Cisneros-Chumacero, Juan D Millan-Landeo, Nayra Quispe-Yauri, Alba S Zevallos
World Journal of Endocrine Surgery.2023; 15(1): 18. CrossRef
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
Riet Hilhorst, Adrienne van den Berg, Piet Boender, Tom van Wezel, Tim Kievits, Rik de Wijn, Rob Ruijtenbeek, Willem E. Corver, Hans Morreau
Cancers.2023; 15(18): 4477. CrossRef
Agrin is a novel oncogenic protein in thyroid cancer
Anna Adamiok‑Ostrowska, Małgorzata Grzanka, Barbara Czarnocka
Oncology Letters.2023;[Epub] CrossRef
Investigation of pre‐operative demographic, biochemical, sonographic and cytopathological findings in low‐risk thyroid neoplasms
Muzaffer Serdar Deniz, Didem Özdemir, Narin Nasıroğlu İmga, Hüsniye Başer, Fatma Neslihan Çuhacı Seyrek, Ayşegül Aksoy Altınboğa, Oya Topaloğlu, Reyhan Ersoy, Bekir Çakır
Clinical Endocrinology.2023; 99(5): 502. CrossRef
The Asian Thyroid Working Group, from 2017 to 2023
Kennichi Kakudo, Chan Kwon Jung, Zhiyan Liu, Mitsuyoshi Hirokawa, Andrey Bychkov, Huy Gia Vuong, Somboon Keelawat, Radhika Srinivasan, Jen-Fan Hang, Chiung-Ru Lai
Journal of Pathology and Translational Medicine.2023; 57(6): 289. CrossRef
Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma
Marco De Martino, Simona Pellecchia, Myriam Decaussin-Petrucci, Domenico Testa, Nathalia Meireles Da Costa, Pierlorenzo Pallante, Paolo Chieffi, Alfredo Fusco, Francesco Esposito
Cell Cycle.2023; 22(23-24): 2552. CrossRef
RESULTS OF A MORPHOLOGICAL STUDY OF THE THYROID GLAND IN PATIENTS WITH AUTOIMMUNE THYROIDITIS
F. G. Sadikhov
World of Medicine and Biology.2023; 19(86): 137. CrossRef
Anaplastik Tiroid Karsinomu Tanısında Morfolojik ve İmmünohistokimyasal Bulguların Yeri: 10 Yıllık Seri
Özlem SARAYDAROĞLU, Rabia DÖLEK, Özen ÖZ GÜL, Ercüment GÜRLÜLER
Uludağ Üniversitesi Tıp Fakültesi Dergisi.2023; 49(3): 411. CrossRef
The Efficacy of ACR TI-RADS in the Management of Suspected Thyroid Nodules and Its Correlation With the Bethesda Scoring System
Emrah Karatay, Mirkhalig Javadov, Kinyas Kartal
Journal of Diagnostic Medical Sonography.2022; 38(4): 309. CrossRef
Systematic evaluation of the anti-tumor effect of Phellinus linteus polysaccharide in thyroid carcinoma in vitro
Kun Yu, Zhuo Tan, Ying Xin
Molecular Biology Reports.2022; 49(4): 2785. CrossRef
Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients
Xun Weng, YangYang, Yujiao Cai, Fu Wang
Disease Markers.2022; 2022: 1. CrossRef
Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin
Sheng-Yao Cheng, Alexander T. H. Wu, Gaber El-Saber Batiha, Ching-Liang Ho, Jih-Chin Lee, Halimat Yusuf Lukman, Mohammed Alorabi, Abdullah N. AlRasheedi, Jia-Hong Chen
Biology.2022; 11(2): 324. CrossRef
Retrospective evaluation of radioactive iodine ablation therapy in the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) and Thyroid tumors with uncertain malignity potential
Mehmet Refik GÖKTUĞ, Özen ÖZ GÜL, Soner CANDER
Turkish Journal of Internal Medicine.2022; 4: 88. CrossRef
Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?
Małgorzata Grzanka, Anna Stachurska-Skrodzka, Anna Adamiok-Ostrowska, Ewa Gajda, Barbara Czarnocka
International Journal of Molecular Sciences.2022; 23(6): 3262. CrossRef
Thyroid Cancer Detection in a Routine Clinical Setting: Performance of ACR TI-RADS, FNAC, and Molecular Testing in Prospective Cohort Study
Tereza Grimmichova, Petra Pacesova, Martin Hill, Barbora Pekova, Marketa Vankova, Jitka Moravcova, Jana Vrbikova, Zdenek Novak, Karolina Mastnikova, Eliska Vaclavikova, Josef Vcelak, Bela Bendlova, Jana Drozenova, Vlasta Sykorova
Biomedicines.2022; 10(5): 954. CrossRef
Advantages of Small Incision Surgery in Thyroid Tumors
Wen Feng, Yuan Feng, Qixian Diao, Jian Zhou, Zhaoqi Dong
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Radioactive Iodine Therapy Does not Improve Cancer-specific Survival in Hürthle Cell Carcinoma of the Thyroid
Xiaofei Wang, Xun Zheng, Jingqiang Zhu, Zhihui Li, Tao Wei
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3144. CrossRef
Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer
Mohammad Hussein, Lauren Mueller, Peter P. Issa, Muhib Haidari, Lily Trinh, Eman Toraih, Emad Kandil
Biomedicines.2022; 10(8): 1984. CrossRef
Ultrasonographic characteristics of Hürthle cell neoplasms: prediction of malignancy
Min Je Kim, Jung Hee Shin, Soo Yeon Hahn, Young Lyun Oh, Sun Wook Kim, Tae Hyuk Kim, Yaeji Lim, Sanghyuk Lee
Ultrasonography.2022; 41(4): 689. CrossRef
Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach
Chan Kwon Jung, Andrey Bychkov, Kennichi Kakudo
Endocrinology and Metabolism.2022; 37(5): 703. CrossRef
A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
Faridul Haq, Andrey Bychkov, Chan Kwon Jung
Endocrine Pathology.2022; 33(4): 472. CrossRef
Clinicopathological features and prognostic factors analysis of multiple synchronous distinct subtypes of primary thyroid carcinoma
Quanwei Dai, Xinghao Fu, Yalei Ding, Qi He, Xinguang Qiu
Endocrine.2022; 79(3): 491. CrossRef
Prevalence of Thyroid Lesions in Thyroidectomy Specimens - A Histomorphological Study in Urban Industrial Area
Shirish Sahebrao Chandanwale, Diva Sutreja, Payal Patel, Anubhaw Verma, Sushma Kulkarni
Journal of Head & Neck Physicians and Surgeons.2022; 10(1): 80. CrossRef
Best Achievements in Clinical Thyroidology in 2020
Eun Kyung Lee, Young Joo Park
Endocrinology and Metabolism.2021; 36(1): 30. CrossRef
High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid
Ja-Seong Bae, Seung-Hyun Jung, Mitsuyoshi Hirokawa, Andrey Bychkov, Akira Miyauchi, Sohee Lee, Yeun-Jun Chung, Chan Kwon Jung
Endocrine Pathology.2021; 32(3): 336. CrossRef
Deep Learning Fast Screening Approach on Cytological Whole Slides for Thyroid Cancer Diagnosis
Yi-Jia Lin, Tai-Kuang Chao, Muhammad-Adil Khalil, Yu-Ching Lee, Ding-Zhi Hong, Jia-Jhen Wu, Ching-Wei Wang
Cancers.2021; 13(15): 3891. CrossRef
How to identify indolent thyroid tumors unlikely to recur and cause cancer death immediately after surgery—Risk stratification of papillary thyroid carcinoma in young patients—
Kennichi Kakudo, Zhiyan Liu, Yanhua Bai, Yaqiong Li, Naomi Kitayama, Shinya Satoh, Masahiro Nakashima, Chan Kwon Jung
Endocrine Journal.2021; 68(8): 871. CrossRef
Papillary Thyroid Cancer Prognosis: An Evolving Field
Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo, Flavio Forte, Alberto Santoro, Piergaspare Palumbo, Vito D’Andrea, Salvator
Cancers.2021; 13(21): 5567. CrossRef
Intrasalivary Thymic Carcinoma: A Case Report and Literature Review
Michał Kunc, Alexandra Kamieniecki, Grzegorz Walczak, Tomasz Nowicki, Bartosz Wasąg, Bogusław Mikaszewski, Dominik Stodulski, Wojciech Biernat
Head and Neck Pathology.2021; 16(3): 857. CrossRef

Original Articles

Clinical Study
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis: Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim; Endocrinol Metab. 2020;35(4):830-837. Published online November 18, 2020; DOI: https://doi.org/10.3803/EnM.2020.747

7,403 View
149 Download
8 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC.
Methods
We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of >1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (≥90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM).
Results
Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM.
Conclusion
The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined >3 months after TT considering other prognostic factors.

Citations

Citations to this article as recorded by

Dynamic risk assessment in patients with differentiated thyroid cancer
Erika Abelleira, Fernando Jerkovich
Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79. CrossRef
Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis
Kathryn Graham, Fay Tough, Helena Belikova, Irene Wotherspoon, David Colville, Nicholas Reed
Endocrine Practice.2024; 30(4): 327. CrossRef
Radioiodine ablation after thyroidectomy could be safely abandoned or postponed in selected stage I papillary thyroid carcinoma patients of low-risk group: an observational prospective study
S.M. Cherenko, A.Yu. Glagolieva, D.E. Makhmudov
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(1): 7. CrossRef
Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study
Tao He, Ming Li, Zheng-lian Gao, Xiang-yu Li, Hai-rong Zhong, Cui-shuang Ding, Hua-wei Cai
Nuclear Medicine Communications.2024; 45(9): 779. CrossRef
Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma
Xin Dai, Xinyi Ren, Jinyu Zhang, Yuxin Zheng, Zhengjie Wang, Gang Cheng
Annals of Nuclear Medicine.2024; 38(9): 688. CrossRef
Comparative evaluation of low and high radioiodine doses in differentiated thyroid carcinoma management: A multicenter study
M.B. Al-Osaimi, E.M. Abdelrazek, Ehab M. Attalla, Hosam Salaheldin
Journal of Radiation Research and Applied Sciences.2024; 17(4): 101206. CrossRef
Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
Clinical Oncology.2023; 35(1): 42. CrossRef
Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
Fang Cheng, Juan Xiao, Fengyan Huang, Chunchun Shao, Shouluan Ding, Canhua Yun, Hongying Jia
Cancer Medicine.2022; 11(12): 2386. CrossRef
Delayed (>3 Months) Postoperative Radioactive Iodine Ablation Does Not Impact Clinical Response or Survival in Differentiated Thyroid Cancers
Tatiana Fedorova, Lilah F. Morris-Wiseman
Clinical Thyroidology.2022; 34(10): 456. CrossRef

Endocrine Research
Liver X Receptor β Related to Tumor Progression and Ribosome Gene Expression in Papillary Thyroid Cancer: Seonhyang Jeong, In-Kyu Kim, Hyunji Kim, Moon Jung Choi, Jandee Lee, Young Suk Jo; Endocrinol Metab. 2020;35(3):656-668. Published online August 20, 2020; DOI: https://doi.org/10.3803/EnM.2020.667

9,930 View
143 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Intracellular lipid deposition has been reported in thyroid glands in obese animal and human. To understand the regulatory mechanism of lipid metabolism in thyroid cancer, we investigated the expression status of liver X receptor (LXR) and analyzed its clinicopathological characteristics and molecular biological features.
Methods
Expression status of LXR and its transcriptional targets in human cancers were analyzed using The Cancer Genome Atlas (TCGA). The gene-sets related to high LXRβ expression was investigated by gene set enrichment analysis (GSEA) using Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways and gene ontology biologic process. Quantitative reverse transcription polymerase chain reaction was performed in thyroid cancer samples using our validation cohort.
Results
In contrast to low expression of LXRα, LXRβ was highly expressed in thyroid cancer compared to the other types of human cancers. High LXRβ expression was correlated with the expression of LXRβ transcriptional targets genes, such as apolipoprotein C1 (APOC1), APOC2, apolipoprotein E (APOE), ATP binding cassette subfamily G member 8 (ABCG8), sterol regulatory elementbinding protein 1c (SREBP1c), and SPOT14. Furthermore, High LXRβ expression group indicated poor clinicopathological characteristics and aggressive molecular biological features independently from the drive mutation status. Mechanistically, high LXRβ expression was coordinately related to ribosome-related gene sets.
Conclusion
The mechanistic link between LXRβ and ribosomal activity will be addressed to develop new diagnostic and therapeutic targets in thyroid cancers.

Citations

Citations to this article as recorded by

Bioinformatic analysis of serpina1 expression in papillary thyroid carcinoma and its potential association with Hashimoto's thyroiditis
Xiuyuan Du, Wanjun Chen
Discover Oncology.2025;[Epub] CrossRef
ApoC1 promotes glioma metastasis by enhancing epithelial-mesenchymal transition and activating the STAT3 pathway
Rui Liang, Guofeng Zhang, Wenhua Xu, Weibing Liu, Youjia Tang
Neurological Research.2023; 45(3): 268. CrossRef
The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice
Lyndsey A. Reich, Ana S. Leal, Edmund Ellsworth, Karen T. Liby
International Journal of Molecular Sciences.2023; 24(5): 4298. CrossRef
The Role of Apolipoproteins in the Commonest Cancers: A Review
Nour M. Darwish, Mooza Kh. Al-Hail, Youssef Mohamed, Rafif Al Saady, Sara Mohsen, Amna Zar, Layla Al-Mansoori, Shona Pedersen
Cancers.2023; 15(23): 5565. CrossRef
Apolipoproteins: New players in cancers
Yingcheng He, Jianrui Chen, Yanbing Ma, Hongping Chen
Frontiers in Pharmacology.2022;[Epub] CrossRef
Simultaneous Expression of Long Non-Coding RNA FAL1 and Extracellular Matrix Protein 1 Defines Tumour Behaviour in Young Patients with Papillary Thyroid Cancer
Seonhyang Jeong, Seul-Gi Lee, Hyunji Kim, Gibbeum Lee, Sunmi Park, In-Kyu Kim, Jandee Lee, Young-Suk Jo
Cancers.2021; 13(13): 3223. CrossRef
Using BioPAX-Parser (BiP) to enrich lists of genes or proteins with pathway data
Giuseppe Agapito, Mario Cannataro
BMC Bioinformatics.2021;[Epub] CrossRef
Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer
Mian Liu, Rooh Afza Khushbu, Pei Chen, Hui-Yu Hu, Neng Tang, Deng-jie Ou-yang, Bo Wei, Ya-xin Zhao, Peng Huang, Shi Chang
Frontiers in Oncology.2021;[Epub] CrossRef
Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment
Lisha Bao, Tong Xu, Xixuan Lu, Ping Huang, Zongfu Pan, Minghua Ge
Frontiers in Oncology.2021;[Epub] CrossRef
Cooperative Subtype Switch of Thyroid Hormone Receptor and Nuclear Receptor Corepressor Related Epithelial–Mesenchymal Transition in Papillary Thyroid Cancer
Seonhyang Jeong, Seul Gi Lee, Hyunji Kim, Gibbeum Lee, Sunmi Park, In-Kyu Kim, Jandee Lee, Young Suk Jo
International Journal of Thyroidology.2021; 14(2): 152. CrossRef

Clinical Study
Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer: Sunghwan Suh, Tae Sik Goh, Yun Hak Kim, Sae-Ock Oh, Kyoungjune Pak, Ju Won Seok, In Joo Kim; Endocrinol Metab. 2020;35(2):435-442. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.435; Correction in: Endocrinol Metab 2023;38(2):287

8,361 View
145 Download
4 Web of Science
3 Crossref

Abstract PDF PubReader ePub

Background
The aim of this study was to develop a scoring system to stratify the risk of papillary thyroid cancer (PTC) and to select the proper management.
Methods
We performed a systematic search of MEDLINE and Embase. Data regarding patients’ prognoses were obtained from the included studies. Odds ratios (ORs) with statistical significance were extracted from the publications. To generate a risk scoring system (RSS), ORs were summed (RSS1), and summed after natural-logarithmic transformation (RSS2). RSS1 and RSS2 were compared to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system and the 2015 American Thyroid Association (ATA) guidelines for thyroid nodules and differentiated thyroid carcinoma.
Results
Five meta-analyses were eligible for inclusion in the study. Eight variables (sex, tumour size, extrathyroidal extension, BRAF mutation, TERT mutation, histologic subtype, lymph node metastasis, and distant metastasis) were included. RSS1 was the best of the analysed models.
Conclusion
We developed and validated a new RSS derived from previous meta-analyses for patients with PTC. This RSS seems to be superior to previously published systems.

Citations

Citations to this article as recorded by

Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers
Devan Diwanji, Emmanuel Carrodeguas, Youngho Seo, Hyunseok Kang, Myat Han Soe, Janet M. Chiang, Li Zhang, Chienying Liu, Spencer C. Behr, Robert R. Flavell
Journal of Clinical Medicine.2024; 13(13): 3963. CrossRef
Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review
Hongxi Wang, Hongyuan Dai, Qianrui Li, Guohua Shen, Lei Shi, Rong Tian
Frontiers in Oncology.2021;[Epub] CrossRef
Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma
Joohyun Woo, Hyeonkyeong Kim, Hyungju Kwon
Journal of Clinical Medicine.2021; 10(21): 5144. CrossRef

Clinical Study
Subclinical Hypothyroidism Affects the Long-Term Outcomes of Patients Who Undergo Coronary Artery Bypass Grafting Surgery but Not Heart Valve Surgery: Hana Kim, Sung Hye Kong, Jae Hoon Moon, Sang Yoon Kim, Kay-Hyun Park, Jun Sung Kim, Joong Haeng Choh, Young Joo Park, Cheong Lim; Endocrinol Metab. 2020;35(2):308-318. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.308

9,823 View
174 Download
12 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The aim of this study was to determine the associations between subclinical hypothyroidism (SCH) and long-term cardiovascular outcomes after coronary artery bypass grafting (CABG) or heart valve surgery (HVS).
Methods
We retrospectively reviewed and compared all-cause mortality, cardiovascular mortality, and cardiovascular events in 461 patients who underwent CABG and 104 patients who underwent HVS.
Results
During a mean±standard deviation follow-up duration of 7.6±3.8 years, there were 187 all-cause deaths, 97 cardiovascular deaths, 127 major adverse cardiovascular events (MACE), 11 myocardial infarctions, one unstable angina, 70 strokes, 30 hospitalizations due to heart failure, 101 atrial fibrillation, and 33 coronary revascularizations. The incidence of all-cause mortality after CABG was significantly higher in patients with SCH (n=36, 55.4%) than in euthyroid patients (n=120, 30.3%), with a hazard ratio of 1.70 (95% confidence interval, 1.10 to 2.63; P=0.018) after adjustment for age, sex, current smoking status, body mass index, underlying diseases, left ventricular dysfunction, and emergency operation. Interestingly, low total triiodothyronine (T3) levels in euthyroid patients who underwent CABG were significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and MACE, but those associations were not observed in HVS patients. Both free thyroxine and thyroid-stimulating hormone levels in euthyroid patients were not related with any cardiovascular outcomes in either the CABG or HVS group.
Conclusion
SCH or low total T3 might be associated with a poor prognosis after CABG, but not after HVS, implying that preoperative thyroid hormonal status may be important in ischemic heart disease patients.

Citations

Citations to this article as recorded by

The impact of thyroid function on surgical prognosis in patients undergoing cardiac and major vascular surgeries
Qi Sun, Wei Wang, Xiaoming Mao, Hao Liu
Journal of Cardiothoracic Surgery.2025;[Epub] CrossRef
Subclinical hypothyroidism and clinical outcomes after cardiac surgery: A systematic review and meta-analysis
Michele Dell’Aquila, Camilla S. Rossi, Tulio Caldonazo, Gianmarco Cancelli, Lamia Harik, Giovanni J. Soletti, Kevin R. An, Jordan Leith, Hristo Kirov, Mudathir Ibrahim, Michelle Demetres, Arnaldo Dimagli, Mohamed Rahouma, Mario Gaudino
JTCVS Open.2024; 18: 64. CrossRef
Impact of subclinical hypothyroidism on outcomes after coronary artery bypass grafting: a systematic review and meta-analysis
Muhammad O. LARIK, Abdul R. SHAHID, Moeez I. SHIRAZ, Maryam UROOJ
The Journal of Cardiovascular Surgery.2024;[Epub] CrossRef
The Association Between Hypothyroidism Treatment and Mortality in Patients Hospitalized in Surgical Wards
Hiba Masri-Iraqi, Yaron Rudman, Carmel Friedrich Dubinchik, Idit Dotan, Talia Diker-Cohen, Liat Sasson, Tzipora Shochat, Ilan Shimon, Eyal Robenshtok, Amit Akirov
Endocrine Research.2023; 48(2-3): 68. CrossRef
Mid-term outcomes of patients with subclinical hypothyroidism after coronary bypass surgery
Dong Zhao, Wei Zhao, Chuangshi Wang, Fei Xu, Wei Zhao, Xieraili Tiemuerniyazi, Hao Ma, Wei Feng
Interdisciplinary CardioVascular and Thoracic Surgery.2023;[Epub] CrossRef
Thyroid Pathology in High-Risk Cardiac Surgery Patients with Coronary Artery Disease
Olena K. Gogayeva, Anatoliy V. Rudenko, Vasyl V. Lazoryshynets, Serhii A. Rudenko, Tetiana A. Andrushchenko
Ukrainian Journal of Cardiovascular Surgery.2022; 30(1 (46)): 9. CrossRef
High-TSH Subclinical Hypothyroidism Is Associated With Postoperative Mortality in Acute Type A Aortic Dissection
Shi-Pan Wang, Yuan Xue, Hai-Yang Li, Wen-Jian Jiang, Hong-Jia Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Triiodothyronine improves contractile recovery of human atrial trabeculae after hypoxia/reoxygenation
Petra Kleinbongard, Philipp Kuthan, Chantal Eickelmann, Philipp Jakobs, Joachim Altschmied, Judith Haendeler, Arjang Ruhparwar, Matthias Thielmann, Gerd Heusch
International Journal of Cardiology.2022; 363: 159. CrossRef
Hypothyroidism Is Correlated with Ventilator Complications and Longer Hospital Days after Coronary Artery Bypass Grafting Surgery in a Relatively Young Population: A Nationwide, Population-Based Study
Jiun-Yu Lin, Pei-Chi Kao, Yi-Ting Tsai, Chi-Hsiang Chung, Wu-Chien Chien, Chih-Yuan Lin, Chieh-Hua Lu, Chien-Sung Tsai
Journal of Clinical Medicine.2022; 11(13): 3881. CrossRef
Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence
Patrick Müller, Melvin Khee-Shing Leow, Johannes W. Dietrich
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape
Won Sang Yoo, Hyun Kyung Chung
Endocrinology and Metabolism.2021; 36(3): 500. CrossRef

Clinical Study
Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service: Jung Hee Kim, Hyemi Moon, Junghyun Noh, Juneyoung Lee, Sin Gon Kim; Endocrinol Metab. 2020;35(1):157-164. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.157

12,361 View
226 Download
37 Web of Science
34 Crossref

Abstract PDF PubReader ePub

Background

Pheochromocytomas and paragangliomas (PPGLs) are rare endocrine tumors originating from chromaffin cells. PPGLs are associated with a high mortality rate and several complications. To date, no epidemiological studies have been conducted on PPGLs in Asia. This study aimed to investigate the epidemiology and prognosis of PPGLs in Korea using nationwide data.

Methods

Using the National Health Insurance Service Database, subjects with a principal diagnosis of PPGLs on two or more occasions between 2003 and 2014 who satisfied the operational definition of PPGLs were included. Incidence, prevalence, complications, metastasis, and mortality were investigated.

Results

In total, 1048 subjects with a mean age of 47.6±16.1 years were included. There was no sex preponderance. The overall prevalence of PPGLs was 2.13 per 100,000 persons, and the overall age-standardized incidence rate was 0.18 per 100,000 person-years. Malignant PPGLs accounted for 17.7% (185 of 1,048) of cases, and 94 subjects exhibited metastasis at the time of diagnosis. Among initially non-metastatic PPGLs, 9.5% (nine of 954) eventually metastasized after a mean duration of 78.1±41.4 months. The 5-year survival rates for non-metastatic and metastatic PPGLs at diagnosis were 97% and 84%, respectively. Multivariable Cox regression models adjusted for covariates showed that metastatic PPGLs were associated with a 2.40-fold higher risk of mortality than non-metastatic PPGLs (95% confidence interval, 1.38 to 4.17; P=0.002).

Conclusion

PPGLs are rare in Korea, and the prognosis of these endocrine tumors varies depending on whether they are benign or malignant. This epidemiological study paves the way for further research on PPGLs.

Citations

Citations to this article as recorded by

Digital Phenotyping of Rare Endocrine Diseases Across International Data Networks and the Effect of Granularity of Original Vocabulary
Seunghyun Lee, Namki Hong, Gyu Seop Kim, Jing Li, Xiaoyu Lin, Sarah Seager, Sungjae Shin, Kyoung Jin Kim, Jae Hyun Bae, Seng Chan You, Yumie Rhee, Sin Gon Kim
Yonsei Medical Journal.2025; 66(3): 187. CrossRef
Prediction of postoperative myocardial injury in patients undergoing laparoscopic pheochromocytoma/paraganglioma resection: protocol for an ambispective cohort study
Ling Lan, Ye Ma, Yifei Zhao, Yaohan Li, Yi Zhang, Le Shen, Yuelun Zhang, Yuguang Huang
BMJ Open.2025; 15(2): e091975. CrossRef
Elevated Fracture Risks in Patients Using Inhaled Corticosteroids: A Korean Nationwide Study
Sung Hye Kong, Ae Jeong Jo, Chan Mi Park, Kyun Ik Park, Ji Eun Yun, Jung Hee Kim
Endocrinology and Metabolism.2025; 40(1): 82. CrossRef
Differences in Clinical Presentation Between Pheochromocytomas and Paragangliomas
Vincent E. D. Pihlblad, Jan Calissendorff, Henrik Falhammar
Clinical Endocrinology.2025; 103(5): 651. CrossRef
The effect of primary tumor resection on overall survival in metastatic pheochromocytoma and paraganglioma: A population-based study
Hexiang Bai, Zhihong Liu, Xu Liu, Yige Jia, Yuchun Zhu, Xiang Li, Kan Wu
Surgery.2025; 187: 109637. CrossRef
Pheochromocytoma-Induced Leukocytosis With Concurrent Severe Eosinophilia: A Case Report
Nouf Alnaqeeb, Mohamed M Abd Elhamid, Ihab AImagdub, Randa Ali
Cureus.2025;[Epub] CrossRef
Analysis of the clinical characteristics of bone metastases after pheochromocytoma/paraganglioma surgery
Longmin Li, Hongbo Gao, Yujun Shao, Xiayang Zhu
Frontiers in Endocrinology.2025;[Epub] CrossRef
Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study
Seung Shin Park, Chang Ho Ahn, Seunghoo Lee, Woochang Lee, Won Woong Kim, Yu‐Mi Lee, Su Jin Kim, Tae‐Yon Sung, Kyu Eun Lee, Jung Hee Kim, Seung Hun Lee, Jung‐Min Koh
Journal of Internal Medicine.2024; 296(1): 68. CrossRef
Seventy years of pheochromocytomas and paragangliomas in Argentina. The FRENAR database
V.C. de Miguel, L.S. Aparicio, G. Sansó, A.L. Paissan, S.N. Lupi, S.H. Belli, J. Tkatch, M.J. Marín, M.B. Barontini
Hipertensión y Riesgo Vascular.2024; 41(3): 170. CrossRef
Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients
Wolfgang Raber, Raphael Schendl, Melisa Arikan, Andreas Scheuba, Peter Mazal, Valerie Stadlmann, Reinhard Lehner, Petra Zeitlhofer, Sabina Baumgartner-Parzer, Cornelia Gabler, Harald Esterbauer
Frontiers in Endocrinology.2024;[Epub] CrossRef
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinology and Metabolism.2023; 38(1): 10. CrossRef
Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician
Sona Sharma, Lauren Fishbein
Endocrine Practice.2023; 29(12): 999. CrossRef
Pheochromocytoma: a changing perspective and current concepts
Andreas Kiriakopoulos, Periklis Giannakis, Evangelos Menenakos
Therapeutic Advances in Endocrinology and Metabolism.2023;[Epub] CrossRef
Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas
Gildas Gabiache, Charline Zadro, Laura Rozenblum, Delphine Vezzosi, Céline Mouly, Matthieu Thoulouzan, Rosine Guimbaud, Philippe Otal, Lawrence Dierickx, Hervé Rousseau, Christopher Trepanier, Laurent Dercle, Fatima-Zohra Mokrane
Cancers.2023; 15(18): 4666. CrossRef
Trends in the incidence of adrenocortical carcinoma and pheochromocytoma/paraganglioma in Taiwan
Chung-Hsin Tsai, Tun-Sung Huang, Shih-Ping Cheng
Formosan Journal of Surgery.2023; 56(5): 147. CrossRef
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
Anri Inaki, Tohru Shiga, Yoshito Tsushima, Megumi Jinguji, Hiroshi Wakabayashi, Daiki Kayano, Norihito Akatani, Takafumi Yamase, Yuji Kunita, Satoru Watanabe, Tomo Hiromasa, Hiroshi Mori, Kenji Hirata, Shiro Watanabe, Tetsuya Higuchi, Hiroyasu Tomonaga, S
Annals of Nuclear Medicine.2022; 36(3): 267. CrossRef
Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance
Jan Calissendorff, Carl Christofer Juhlin, Irina Bancos, Henrik Falhammar
Cancers.2022; 14(4): 917. CrossRef
Characteristics of Intraoperative Hemodynamic Instability in Postoperatively Diagnosed Pheochromocytoma and Sympathetic Paraganglioma Patients
Jung Hee Kim, Hyung-Chul Lee, Su-jin Kim, Kyu Eun Lee, Kyeong Cheon Jung
Frontiers in Endocrinology.2022;[Epub] CrossRef
Change of Computed Tomography-Based Body Composition after Adrenalectomy in Patients with Pheochromocytoma
Yousun Ko, Heeryoel Jeong, Seungwoo Khang, Jeongjin Lee, Kyung Won Kim, Beom-Jun Kim
Cancers.2022; 14(8): 1967. CrossRef
Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years
Abdul Rahman Al Subhi, Veronica Boyle, Marianne S Elston
Journal of the Endocrine Society.2022;[Epub] CrossRef
Incidence and risk factors for myocardial injury after laparoscopic adrenalectomy for pheochromocytoma: A retrospective cohort study
Ling Lan, Qian Shu, Chunhua Yu, Lijian Pei, Yuelun Zhang, Li Xu, Yuguang Huang
Frontiers in Oncology.2022;[Epub] CrossRef
The Clinical Characteristics of Pheochromocytomas and Paragangliomas with Negative Catecholamines
Lin Zhao, Xiaoran Zhang, Xu Meng, Ting Zhang, Hua Fan, Qiongyu Zhang, Yecheng Liu, Xianliang Zhou, Huadong Zhu
Journal of Clinical Medicine.2022; 11(19): 5583. CrossRef
A midline ectopic paraganglioma
Christina SANT FOURNIER, Matthias FARRUGIA, Kimberley PACE, Christian CAMENZULI, Alexander R. ATTARD
Chirurgia.2022;[Epub] CrossRef
Non-Selective Alpha-Blockers Provide More Stable Intraoperative Hemodynamic Control Compared with Selective Alpha1-Blockers in Patients with Pheochromocytoma and Paraganglioma: A Single-Center Retrospective Cohort Study with a Propensity Score-Matched Ana
Yang Yang, Jie Zhang, Liqun Fang, Xue Jia, Wensheng Zhang
Drug Design, Development and Therapy.2022; Volume 16: 3599. CrossRef
Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study
Andreas Ebbehoj, Kirstine Stochholm, Sarah Forslund Jacobsen, Christian Trolle, Peter Jepsen, Maciej Grzegorz Robaczyk, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Reimar Wernich Thomsen, Esben Søndergaard, Per Løgstrup Poulsen
The Journal of Clinical Endocrinology & Metabolism.2021; 106(5): e2251. CrossRef
Determinants of anxiety and depression among pheochromocytoma patients
Siming Jia, Chengbai Li, Zhuqing Lei, Qiang Xia, Yuqing Jiang
Medicine.2021; 100(3): e24335. CrossRef
Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases
Akiyuki Kawashima, Masakatsu Sone, Nobuya Inagaki, Kentaro Okamoto, Mika Tsuiki, Shoichiro Izawa, Michio Otsuki, Shintaro Okamura, Takamasa Ichijo, Takuyuki Katabami, Yoshiyu Takeda, Takanobu Yoshimoto, Mitsuhide Naruse, Akiyo Tanabe
Endocrine.2021; 74(1): 155. CrossRef
Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
Endocrinology and Metabolism.2021; 36(2): 322. CrossRef
Clinical Presentation and Perioperative Management of Pheochromocytomas and Paragangliomas: A 4-Decade Experience
Thomas Uslar, Ignacio F San Francisco, Roberto Olmos, Stefano Macchiavelo, Alvaro Zuñiga, Pablo Rojas, Marcelo Garrido, Alvaro Huete, Gonzalo P Mendez, Ignacio Cortinez, José Tomás Zemelman, Joaquín Cifuentes, Fernando Castro, Daniela Olivari, José Miguel
Journal of the Endocrine Society.2021;[Epub] CrossRef
Pheochromocytoma
Zhonghua Liu, Junsheng Ma, Camilo Jimenez, Miao Zhang
American Journal of Surgical Pathology.2021; 45(9): 1155. CrossRef
Perioperative hemodynamic instability in pheochromocytoma and sympathetic paraganglioma patients
Jung Hee Kim, Hyung-Chul Lee, Su-jin Kim, Soo Bin Yoon, Sung Hye Kong, Hyeong Won Yu, Young Jun Chai, June Young Choi, Kyu Eun Lee, Kwang-Woong Lee, Seung-Kee Min, Chan Soo Shin, Kyu Joo Park
Scientific Reports.2021;[Epub] CrossRef
Changes in the Nociception Level Index During Surgical Resection of Paragangliomas: A Case Report
Rita Saynhalath, Umar H. Khan, Gijo Alex, Joseph T. Murphy, Peter Szmuk
A&A Practice.2021; 15(11): e01542. CrossRef
Hypertension Cure and Reducing Pill Burden after Adrenalectomy for Endocrine Hypertension of Adrenal Origin: A Comparative Study from an Asian and UK Cohort
Kee Y Ngiam, Ciaran Durand, Titus C Vasciuc, Chia H Tai, Raluca Orpean, Fiona Eatock, Mehak Mahipal, Tan W Boon
World Journal of Endocrine Surgery.2021; 13(1): 9. CrossRef
A Brief Overview of the Epidemiology of Pheochromocytoma and Paraganglioma in Korea
Yun Mi Choi
Endocrinology and Metabolism.2020; 35(1): 95. CrossRef

Review Article

Thyroid
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer: Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong; Endocrinol Metab. 2020;35(1):14-25. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.14

10,819 View
163 Download
16 Web of Science
12 Crossref

Abstract PDF PubReader ePub

The increased incidence of thyroid cancer is a worldwide phenomenon; however, the issue of overdiagnosis has been most prominent in South Korea. The age-standardized mortality rate of thyroid cancer in Korea steeply increased from 1985 to 2004 (from 0.17 per 100,000 to 0.85 per 100,000), and then decreased until 2015 to 0.42 per 100,000, suggesting that early detection reduced mortality. However, early detection of thyroid cancer may be cost-ineffective, considering its very high prevalence and indolent course. Therefore, risk stratification and tailored management are vitally important, but many prognostic markers can only be evaluated postoperatively. Discovery of preoperative marker(s), especially for small cancers, is the most important unmet clinical need for thyroid cancer. Herein, we discuss some such factors that we recently discovered. Another unmet clinical need is better treatment of radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) and undifferentiated cancers. Although sorafenib and lenvatinib are available, better drugs are needed. We found that phosphoglycerate dehydrogenase, a critical enzyme for serine biosynthesis, could be a novel therapeutic target, and that the lymphocyte-to-monocyte ratio is a prognostic marker of survival in patients with anaplastic thyroid carcinoma or RAIR DTC. Deeper insights are needed into tumor-host interactions in thyroid cancer to improve treatment.

Citations

Citations to this article as recorded by

Macrophage-Induced Carboxypeptidase A4 Promotes the Progression of Anaplastic Thyroid Cancer
Yeon-Sook Choi, Min Ji Jeon, Woo Kyung Lee Doolittle, Dong Eun Song, Kyunggon Kim, Won Bae Kim, Won Gu Kim
Thyroid®.2024; 34(9): 1150. CrossRef
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
Thyroid.2023; 33(1): 91. CrossRef
Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Integration of ultrasound-based radiomics with clinical features for predicting cervical lymph node metastasis in postoperative patients with differentiated thyroid carcinoma
Fengjing Fan, Fei Li, Yixuan Wang, Zhengjun Dai, Yuyang Lin, Lin Liao, Bei Wang, Hongjun Sun
Endocrine.2023; 84(3): 999. CrossRef
Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
Seung-Jin Park, Yea Eun Kang, Jeong-Hwan Kim, Jong-Lyul Park, Seon-Kyu Kim, Seung-Woo Baek, In Sun Chu, Shinae Yi, Seong Eun Lee, Young Joo Park, Eun-Jae Chung, Jin Man Kim, Hye Mi Ko, Je-Ryong Kim, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Bon Seok Koo
Clinical and Experimental Otorhinolaryngology.2022; 15(2): 183. CrossRef
Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2022; 29(12): 7835. CrossRef
Carboxy terminus of HSP70‐interacting protein (CHIP) attenuates the stemness of thyroid cancer cells through decreasing OCT4 protein stability
Ying Xu, Gang Xu, Huimin Dang, Wei Qu, Dan Chang, Xin He, Minmin Li, Qian Wang
Environmental Toxicology.2021; 36(4): 686. CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
Clinical Endocrinology.2021; 95(6): 882. CrossRef
80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53
Kun Yu, Hongjiang Lu, Yanhong Chen, Ying Xin, Zhuo Tan, Qiong Yang
Frontiers in Bioscience-Landmark.2021;[Epub] CrossRef
CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma
Young Mun Jeong, Haejin Cho, Tae-Min Kim, Yourha Kim, Sora Jeon, Andrey Bychkov, Chan Kwon Jung
Cancers.2020; 12(10): 3042. CrossRef
The Role of Exosomes in Thyroid Cancer and Their Potential Clinical Application
Kaixiang Feng, Runsheng Ma, Lele Zhang, Hongqiang Li, Yifeng Tang, Gongbo Du, Dongpeng Niu, Detao Yin
Frontiers in Oncology.2020;[Epub] CrossRef

Original Articles

Clinical Study
Protein Expression of Cyclin B1, Transferrin Receptor, and Fibronectin Is Correlated with the Prognosis of Adrenal Cortical Carcinoma: Sun Joon Moon, Jung Hee Kim, Sung Hye Kong, Chan Soo Shin; Endocrinol Metab. 2020;35(1):132-141. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.132

13,463 View
103 Download
13 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Adrenal cortical carcinoma (ACC) is a rare cancer with a variable prognosis. Several prognostic factors of ACC have been previously reported, but a proteomic analysis has not yet been performed. This study aimed to investigate prognostic biomarkers for ACC using a proteomic approach.

Methods

We used reverse-phase protein array data from The Cancer Proteome Atlas, and identified differentially expressed proteins in metastatic ACCs. Multivariate Cox regression analysis adjusted by age and staging was used for survival analysis, and the C-index and category-free net reclassification improvement (cfNRI) were utilized to evaluate additive prognostic value.

Results

In 46 patients with ACC, cyclin B1, transferrin receptor (TfR1), and fibronectin were significantly overexpressed in patients with distant metastasis. In multivariate models, high expression of cyclin B1 and TfR1 was significantly associated with mortality (hazard ratio [HR], 6.13; 95% confidence interval [CI], 1.02 to 36.7; and HR, 6.59; 95% CI, 1.14 to 38.2; respectively), whereas high fibronectin expression was not (HR, 3.92; 95% CI, 0.75 to 20.4). Combinations of high cyclin B1/high TfR1, high cyclin B1/high fibronectin, and high TfR1/high fibronectin were strongly associated with mortality ([HR, 13.72; 95% CI, 1.89 to 99.66], [HR, 9.22; 95% CI, 1.34 to 63.55], and [HR, 18.59; 95% CI, 2.54 to 135.88], respectively). In reclassification analyses, cyclin B1, TfR1, fibronectin, and combinations thereof improved the prognostic performance (C-index, 0.78 to 0.82–0.86; cfNRI, all P values <0.05).

Conclusion

In ACC patients, the overexpression of cyclin B1, TfR1, and fibronectin and combinations thereof were associated with poor prognosis.

Citations

Citations to this article as recorded by

Overexpression of Transferrin Receptor in Esophageal Squamous Cell Cancer Suggests Poor Prognosis and Potential Therapy
Naoki Ikenaga, Tsuyoshi Takahashi, Koji Tanaka, Satoshi Serada, Minoru Fujimoto, Kota Momose, Kotaro Yamashita, Tomoki Makino, Takuro Saito, Kazuyoshi Yamamoto, Yukinori Kurokawa, Kiyokazu Nakajima, Tomomi Fujii, Eiichi Morii, Tetsuji Naka, Hidetoshi Eguc
Cancer Science.2025;[Epub] CrossRef
Identification of Key Genes and Related Drugs of Adrenocortical Carcinoma by Integrated Bioinformatics Analysis
Jian-bin Wei, Xiao-chun Zeng, Kui-rong Ji, Ling-yi Zhang, Xiao-min Chen
Hormone and Metabolic Research.2024; 56(08): 593. CrossRef
Synthesis and Evaluation of [64Cu]Cu-NOTA-HFn for PET Imaging of Transferrin Receptor 1 Expression in Nasopharyngeal Carcinoma
Yanfang Shen, Renwei Zhou, Lei Bi, Guolong Huang, Min Yang, Zhijun Li, Jijin Yao, Jianzhong Xian, Yifan Qiu, Peizhen Ye, Yongshan Liu, Yuyi Hou, Hongjun Jin, Ying Wang
ACS Omega.2024;[Epub] CrossRef
An affordable label-free ultrasensitive immunosensor based on gold nanoparticles deposited on glassy carbon electrode for the transferrin receptor detection
Abrar Ahmad, Gulam Rabbani, Mazin A. Zamzami, Salman Hosawi, Othman A. Baothman, Hisham Altayeb, Muhammad Shahid Nadeem Akhtar, Varish Ahmad, Mohsin Vahid Khan, Mohammad Ehtisham Khan, Se Hyun Kim
International Journal of Biological Macromolecules.2024; 273: 133083. CrossRef
USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression
Yue Xiao, Xinyi Chen, Weiwei Hu, Wenjing Ma, Qianqian Di, Haimei Tang, Xibao Zhao, Guodong Huang, Weilin Chen
Translational Oncology.2023; 34: 101713. CrossRef
Identification of key genes and pathways in adrenocortical carcinoma: evidence from bioinformatic analysis
Mengsha Yin, Yao Wang, Xinhua Ren, Mingyue Han, Shanshan Li, Ruishuang Liang, Guixia Wang, Xiaokun Gang
Frontiers in Endocrinology.2023;[Epub] CrossRef
Ferritin nanocage based delivery vehicles: From single-, co- to compartmentalized- encapsulation of bioactive or nutraceutical compounds
Hai Chen, Xiaoyi Tan, Xueer Han, Liang Ma, Hongjie Dai, Yu Fu, Yuhao Zhang
Biotechnology Advances.2022; 61: 108037. CrossRef
Effect of Inactivation of Mst1 and Mst2 in the Mouse Adrenal Cortex
Nour Abou Nader, Étienne Blais, Guillaume St-Jean, Derek Boerboom, Gustavo Zamberlam, Alexandre Boyer
Journal of the Endocrine Society.2022;[Epub] CrossRef
Cyclin B1 expression as an independent prognostic factor for lung adenocarcinoma and its potential pathways
Yi Li, Yuanxiu Leng, Yudi Dong, Yongxiang Song, Qiaoyuan Wu, Ni Jiang, Hui Dong, Fang Chen, Qing Luo, Chen Cheng
Oncology Letters.2022;[Epub] CrossRef
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Pierre V. Candelaria, Lai Sum Leoh, Manuel L. Penichet, Tracy R. Daniels-Wells
Frontiers in Immunology.2021;[Epub] CrossRef
Mass Spectrometry-Based Proteomic Discovery of Prognostic Biomarkers in Adrenal Cortical Carcinoma
Han Na Jang, Sun Joon Moon, Kyeong Cheon Jung, Sang Wan Kim, Hyeyoon Kim, Dohyun Han, Jung Hee Kim
Cancers.2021; 13(15): 3890. CrossRef
Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer
Milad Ashrafizadeh, Kiavash Hushmandi, Ebrahim Rahmani Moghadam, Vahideh Zarrin, Sharareh Hosseinzadeh Kashani, Saied Bokaie, Masoud Najafi, Shima Tavakol, Reza Mohammadinejad, Noushin Nabavi, Chia-Ling Hsieh, Atefeh Zarepour, Ehsan Nazarzadeh Zare, Ali Z
Bioengineering.2020; 7(3): 91. CrossRef

Thyroid
Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies: Shinje Moon, Hye Soo Chung, Jae Myung Yu, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Young Joo Park; Endocrinol Metab. 2018;33(4):473-484. Published online November 30, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.4.473

13,952 View
145 Download
73 Web of Science
72 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Epidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC.

Methods

We searched citation databases, including PubMed and Embase, for relevant studies from inception to September 2017. From these studies, we calculated the pooled odds ratios (ORs) of clinicopathologic features and the relative risk (RR) of PTC recurrence with 95% confidence intervals (CIs) using the Mantel-Haenszel method. Additionally, the Higgins I² statistic was used to test for heterogeneity.

Results

The meta-analysis included 71 published studies with 44,034 participants, among whom 11,132 had HT. We observed negative associations between PTC with comorbid HT and extrathyroidal extension (OR, 0.74; 95% CI, 0.68 to 0.81), lymph node metastasis (OR, 0.82; 95% CI, 0.72 to 0.94), distant metastasis (OR, 0.49; 95% CI, 0.32 to 0.76), and recurrence (RR, 0.50; 95% CI, 0.41 to 0.61).

Conclusion

In this meta-analysis, PTC patients with HT appeared to exhibit more favorable clinicopathologic characteristics and a better prognosis than those without HT.

Citations

Citations to this article as recorded by

Impact of chronic lymphocytic thyroiditis on the diagnostic and intraoperative management of papillary thyroid cancer
Tanaz M. Vaghaiwalla, Victoria DeTrolio, Cima Saghira, Mehmet Akcin, Cheng-Bang Chen, Christel M. McGillicuddy, John I. Lew
Surgery.2025; 179: 108937. CrossRef
Investigating the Association Between Hashimoto's Thyroiditis and Papillary Thyroid Cancer
Adriana I. Báez Berríos, Mathilda Monaghan, Margaret Brandwein‐Weber, Maaike van Gerwen
Head & Neck.2025; 47(4): 1214. CrossRef
Papillary thyroid carcinoma with Hashimoto’s thyroiditis: impact and correlation
Shengpeng Yao, Hong Zhang
Frontiers in Endocrinology.2025;[Epub] CrossRef
The effect of the presence of Hashimoto’s thyroiditis on the frequency of papillary thyroid carcinoma subtypes
Zekiye Büşra Şahin, Zeynel Abidin Sayiner, Ersin Akarsu
Folia Medica.2025;[Epub] CrossRef
Bioinformatic analysis of serpina1 expression in papillary thyroid carcinoma and its potential association with Hashimoto's thyroiditis
Xiuyuan Du, Wanjun Chen
Discover Oncology.2025;[Epub] CrossRef
Chronic Lymphocytic Thyroiditis Does Not Worsen Early Surgical Outcomes in Papillary Thyroid Cancer
Tanaz M. Vaghaiwalla, Jonathan Chang, Victoria DeTrolio, Cima Saghira, Mehmet Akcin, Cheng‐Bang Chen, John I. Lew
World Journal of Surgery.2025; 49(9): 2457. CrossRef
Preoperative Clinical Factors Associated With High-Risk Features Predictive of Papillary Thyroid Cancer Recurrence
Jonathan J. Chang, Nora E. Siegler, Elliott M. Henriksen, Cima Saghira, John I. Lew, Tanaz M. Vaghaiwalla
Journal of Surgical Research.2025; 315: 900. CrossRef
Malignancy risk of indeterminate lymph node at the central compartment in patients with thyroid cancer and concomitant sonographic thyroiditis
Jung Hyo Rhim, Ji Ye Lee, Sun‐Won Park, Younghen Lee, So Lyung Jung, Tae Jin Yun, Eun Ju Ha, Jung Hwan Baek, Jinna Kim, Dong Gyu Na, Ji‐hoon Kim
Head & Neck.2024; 46(8): 1922. CrossRef
Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis
Injung Yang, Jae Myung Yu, Hye Soo Chung, Yoon Jung Kim, Yong Kyun Roh, Min Kyu Choi, Sung-ho Park, Young Joo Park, Shinje Moon
Endocrinology and Metabolism.2024; 39(1): 140. CrossRef
Interaction of BANCR in the relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma expression patterns and possible molecular mechanisms
Jiabo Zhang, Lingli Yao, Yu Guo
The Journal of Gene Medicine.2024;[Epub] CrossRef
Association between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis
Jie Liu
Clinical Thyroidology®.2024; 36(1): 26. CrossRef
Predicting central cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto’s thyroiditis: a practical nomogram based on retrospective study
Lirong Wang, Lin Zhang, Dan Wang, Jiawen Chen, Wenxiu Su, Lei Sun, Jue Jiang, Juan Wang, Qi Zhou
PeerJ.2024; 12: e17108. CrossRef
Nomogram to predict central lymph node metastasis in papillary thyroid carcinoma
Dehui Qiao, Xian Deng, Ruichen Liang, Xu Li, Rongjia Zhang, Zhi Lei, Hui Yang, Xiangyu Zhou
Clinical & Experimental Metastasis.2024; 41(5): 613. CrossRef
Utilizing Immunoglobulin G4 Immunohistochemistry for Risk Stratification in Patients with Papillary Thyroid Carcinoma Associated with Hashimoto Thyroiditis
Faridul Haq, Gyeongsin Park, Sora Jeon, Mitsuyoshi Hirokawa, Chan Kwon Jung
Endocrinology and Metabolism.2024; 39(3): 468. CrossRef
Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024
Young Joo Park, Eun Kyung Lee, Young Shin Song, Su Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung,
International Journal of Thyroidology.2024; 17(1): 208. CrossRef
Predictors of lateral lymph node metastasis and skip metastasis in patients with papillary thyroid microcarcinoma
Jee Hee Yoon, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Surgical management of papillary thyroid carcinoma coexisting with Hashimoto’s disease: a single-center retrospective cohort study
Dongdong Zhang, Jixiang Wu, Lin Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Evaluating the Influence of Hashimoto’s Thyroiditis on Clinico‐Pathological Characteristics and Prognostic Outcomes of Middle Eastern Differentiated Thyroid Carcinoma
Sandeep Kumar Parvathareddy, Abdul K. Siraj, Nabil Siraj, Saeeda O. Ahmed, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya, Henrik Falhammar
International Journal of Endocrinology.2024;[Epub] CrossRef
Chronic Lymphocytic Thyroiditis is a Protective Factor for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Propensity Score Matching Analysis
Jian Yu, Xiaoyang Li, Zhijian He, Jie He, Shangrui Rao
British Journal of Hospital Medicine.2024; : 1. CrossRef
Clinicopathological and molecular markers for the identification of Hashimoto’s thyroiditis as a possible predisposing and prognostic factor of papillary thyroid carcinoma
Stavroula Daskalaki, Georgia Kafiri, Maria Venetikou, Apostolos Beloukas, Athina Kladi-Skandali, Fragkiski Anthouli-Anagnostopoulou
Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition.2024; 42(2-3): 43. CrossRef
Biomarkers associated with papillary thyroid carcinoma and Hashimoto’s thyroiditis: Bioinformatic analysis and experimental validation
Bingxin Li, Zhaogen Cai, Yihan Zhang, Ruihua Chen, Shanshan Tang, Feijuan Kong, Wen Li, Li Ding, Lei Chen, Huanbai Xu
International Immunopharmacology.2024; 143: 113532. CrossRef
Risk prediction for central lymph node metastasis in isolated isthmic papillary thyroid carcinoma by nomogram: A retrospective study from 2010 to 2021
Yu Zhao, Wei Shi, Fang Dong, Xiuhua Wang, Chong Lu, Chunping Liu
Frontiers in Endocrinology.2023;[Epub] CrossRef
The evaluation of locoregional tumoral involvement in the cooccurrence of hashimoto thyroiditis with papillary thyroid cancer: a case controlled study
Shirzad Nasiri, Seyed Mostafa Meshkati Yazd, Mahsa Gholami, Sepehr Shahriarirad, Sina Sharghi, Reza Shahriarirad
BMC Endocrine Disorders.2023;[Epub] CrossRef
Hashimoto’s Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma
Peter P. Issa, Mahmoud Omar, Yusef Buti, Mohamed Aboueisha, Ruhul Munshi, Mohammad Hussein, Muhib Haidari, Graham Blair, Chad P. Issa, Mohamed Shama, Eman Toraih, Emad Kandil
Cancers.2023; 15(8): 2371. CrossRef
VITAMIN D AND AUTOIMMUNE THYROIDITIS
K. V. Pivtorak, O. V Ivanhuk O. V
Bulletin of Problems Biology and Medicine.2023; 1(1): 44. CrossRef
Does the Association of Hashimoto's Thyroiditis with Differentiated Thyroid Cancer Really Have a Protective Role?
Ahmet Numan Demir, Zehra Kara, Cem Sulu, Serhat Uysal, Serdar Sahin, Guldana Zulfaliyeva, Oznur Aydin Atar, Nahida Valikhanova, Tulin Ozturk, Hande Mefkure Ozkaya, Mustafa Sait Gonen
Hormone and Metabolic Research.2023; 55(06): 388. CrossRef
Ultrasound, laboratory and histopathological insights in diagnosing papillary thyroid carcinoma in a paediatric population: a single centre follow-up study between 2000-2022
Dominika Januś, Małgorzata Wójcik, Anna Taczanowska-Niemczuk, Aleksandra Kiszka-Wiłkojć, Monika Kujdowicz, Małgorzata Czogała, Wojciech Górecki, Jerzy B. Starzyk
Frontiers in Endocrinology.2023;[Epub] CrossRef
Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
Havva Sezer, Dilek Yazıcı, Tarık Terzioğlu, Serdar Tezelman, Hande Bulut Canbaz, Aslıhan Yerlikaya, Mehmet Onur Demirkol, Yersu Kapran, Bülent Çolakoğlu, Eda Nur Çilingiroğlu, Faruk Alagöl
The American Surgeon™.2023; 89(12): 5996. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Clonal redemption of B cells in cancer
Tyler R. McCaw, Serena Y. Lofftus, Joseph G. Crompton
Frontiers in Immunology.2023;[Epub] CrossRef
Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto’s thyroiditis: a systematic review with meta-analysis
Lukasz Janicki, Agastya Patel, Jarosław Jendrzejewski, Andrzej Hellmann
Frontiers in Endocrinology.2023;[Epub] CrossRef
The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis
Nese E. GULCELIK, Safak AKIN, Kadriye AYDIN, Cisel AYDIN MERICOZ, Yesim G. GULER TEZEL, Aydan USMAN
Minerva Endocrinology.2023;[Epub] CrossRef
Chronic Lymphocytic Thyroiditis and Aggressiveness of Pediatric Differentiated Thyroid Cancer
Richard M. Yeker, Amber D. Shaffer, Pushpa Viswanathan, Selma F. Witchel, Kevin Mollen, Linwah Yip, Sara E. Monaco, Umamaheswar Duvvuri, Jeffrey P. Simons
The Laryngoscope.2022; 132(8): 1668. CrossRef
Bisphenol A drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signaling
Xuan Zhang, Nan Guo, Hao Jin, Renqi Liu, Zhen Zhang, Cheng Cheng, Zhijun Fan, Guopei Zhang, Mingyang Xiao, Shengwen Wu, Yuejiao Zhao, Xiaobo Lu
Journal of Hazardous Materials.2022; 425: 127911. CrossRef
Squamous Differentiation in the Thyroid: Metaplasia, Neoplasia, or Bystander?
Meagan A. Chambers, Peter M. Sadow, Darcy A. Kerr
International Journal of Surgical Pathology.2022; 30(4): 385. CrossRef
Vitamin D Implications and Effect of Supplementation in Endocrine Disorders: Autoimmune Thyroid Disorders (Hashimoto’s Disease and Grave’s Disease), Diabetes Mellitus and Obesity
Dorina Galușca, Mihaela Popoviciu, Emilia Babeș, Mădălina Vidican, Andreea Zaha, Vlad Babeș, Alexandru Jurca, Dana Zaha, Florian Bodog
Medicina.2022; 58(2): 194. CrossRef
Central Compartment Lymph Nodes Have Distinct Metastatic Patterns in Different Age Groups
Caigu Yan, Xianghui He, Zuoyu Chen, Yizeng Wang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Synchronous occurrence of papillary thyroid microcarcinoma, medullary thyroid carcinoma and Hashimoto thyroiditis in a single thyroid: A case report with literature review
Ari M. Abdullah, Rawa M. Ali, Karzan M. Salih, Karukh K. Mohammed, Fahmi H. Kakamad, Abdulwahid M. Salih
International Journal of Surgery Case Reports.2022; 93: 106888. CrossRef
Benign and malignant thyroid nodules with autoimmune thyroiditis
Georgia N. Kassi, Catherine C. Evangelopoulou, Konstantinos D. Papapostolou, Helen J. Karga
Archives of Endocrinology and Metabolism.2022;[Epub] CrossRef
Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
PLOS ONE.2022; 17(6): e0269995. CrossRef
A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer - A Necessity or an Excess
David D. Dolidze, Alexey V. Shabunin, Robert B. Mumladze, Arshak V. Vardanyan, Serghei D. Covantsev, Alexander M. Shulutko, Vasiliy I. Semikov, Khalid M. Isaev, Airazat M. Kazaryan
Frontiers in Oncology.2022;[Epub] CrossRef
Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers
Natália Medeiros Dias Lopes, Hannah Hamada Mendonça Lens, Walison Augusto da Silva Brito, Julya Karen Bianchi, Poliana Camila Marinello, Rubens Cecchini, André Armani, Alessandra Lourenço Cecchini
Clinical and Translational Oncology.2022; 24(12): 2366. CrossRef
Emerging trends and hot spots in autoimmune thyroiditis research from 2000 to 2022: A bibliometric analysis
Qiuxian Li, Wanyu Yang, Jiashu Li, Zhongyan Shan
Frontiers in Immunology.2022;[Epub] CrossRef
The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis
Fabiana Pani, Paola Caria, Yoshinori Yasuda, Miyara Makoto, Stefano Mariotti, Laurence Leenhardt, Solmaz Roshanmehr, Patrizio Caturegli, Camille Buffet
Cancers.2022; 14(17): 4287. CrossRef
Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis
Yuepeng Zhang, Yueli Tian
BMC Endocrine Disorders.2022;[Epub] CrossRef
Elastographic Evaluation of Thyroid Nodules in Children and Adolescents with Hashimoto’s Thyroiditis and Nodular Goiter with Reference to Cytological and/or Histopathological Diagnosis
Hanna Borysewicz-Sańczyk, Beata Sawicka, Filip Bossowski, Janusz Dzięcioł, Artur Bossowski
Journal of Clinical Medicine.2022; 11(21): 6339. CrossRef
Prognostic value of the preoperative and early trends in postoperative serum thyroglobulin antibody levels among patients with papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis
Siyuan Xu, Hui Huang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu
Endocrine.2022; 80(2): 392. CrossRef
What has changed in the last 20 years in the postoperative specimen findings of the papillary thyroid cancer cases? A retrospective analysis
Burak Bakar, Pınar Taşar, Turkay Kırdak, Sadık Kılıçturgay
Turkish Journal of Surgery.2022; 38(4): 345. CrossRef
A nomogram model based on the preoperative clinical characteristics of papillary thyroid carcinoma with Hashimoto's thyroiditis to predict central lymph node metastasis
Wanjun Zhao, Linye He, Jingqiang Zhu, Anping Su
Clinical Endocrinology.2021; 94(2): 310. CrossRef
The Association of Histologically Proven Chronic Lymphocytic Thyroiditis with Clinicopathological Features, Lymph Node Metastasis, and Recurrence Rates of Differentiated Thyroid Cancer
Berna İmge Aydoğan, Adile Begüm Bahçecioğlu Mutlu, Seher Yüksel, Sevim Güllü, Rıfat Emral, Özgür Demir, Mustafa Şahin, Vedia Tonyukuk Gedik, Demet Çorapçıoğlu, Serpil Dizbay Sak, Murat Faik Erdoğan
Endocrine Pathology.2021; 32(2): 280. CrossRef
Beneficial autoimmunity improves cancer prognosis
Laurence Zitvogel, Claude Perreault, Olivera J. Finn, Guido Kroemer
Nature Reviews Clinical Oncology.2021; 18(9): 591. CrossRef
Influence Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: Hashimoto’s Thyroiditis Has a Weak Effect on Central or Lateral Lymph Node Metastasis
Liguang Zhou, Gang Chen, Lei Sheng, Nan Liu, Bin Zhang, Qingdong Zeng, Bo Chen
Cancer Management and Research.2021; Volume 13: 3953. CrossRef
Implications of a background of Hashimoto’s thyroiditis on the current conservative surgical trend towards papillary thyroid carcinoma
Shadi Hamouri, Sohail Bakkar, Almoutuz Aljaafreh, Mohammed Bani Hani, Hussein Heis, Ghazi Qasaimeh, Nasr Alrabadi, Wisam Al Gargaz, Haitham Odat, Yazan Alkurdi, Tarek Manasreh, Mohammad Matalka, Moamin Badwan
Updates in Surgery.2021; 73(5): 1931. CrossRef
Thyroid nodules in childhood‐onset Hashimoto's thyroiditis: Frequency, risk factors, follow‐up course and genetic alterations of thyroid cancer
Yun Jeong Lee, Yeon Jin Cho, You Joung Heo, Eun‐Jae Chung, Young Hun Choi, Jong‐Il Kim, Young Joo Park, Choong Ho Shin, Young Ah Lee
Clinical Endocrinology.2021; 95(4): 638. CrossRef
Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes
Siyuan Xu, Hui Huang, Jiaxin Qian, Yang Liu, Ying Huang, Xiaolei Wang, Shaoyan Liu, Zhengang Xu, Jie Liu
JAMA Network Open.2021; 4(7): e2118526. CrossRef
The Effects of Chronic Lymphocytic Thyroiditis on Clinicopathologic Factors in Papillary Thyroid Cancer
Davut Sakiz, Muhammed Erkam Sencar, Murat Calapkulu, Ilknur Ozturk Unsal, Levent Aktas, Bekir Ucan, Mustafa Ozbek, Erman Cakal
Endocrine Practice.2021; 27(12): 1199. CrossRef
Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto’s Thyroiditis
Xiao-xiong Gan, Ya-yi Li, Si-jin Li, Shi-sen Mo, Jian-hua Feng, Fei Shen, Wen-song Cai, Ye-qian Lai, Bo Xu
Frontiers in Oncology.2021;[Epub] CrossRef
Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model
Fabiana Pani, Yoshinori Yasuda, Giulia Di Dalmazi, Paulina Chalan, Kathleen Gabrielson, Luigi Adamo, Elena Sabini, Stefano Mariotti, Patrizio Caturegli
Endocrinology.2021;[Epub] CrossRef
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
Juliette Paillet, Céleste Plantureux, Sarah Lévesque, Julie Le Naour, Gautier Stoll, Allan Sauvat, Pamela Caudana, Jimena Tosello Boari, Norma Bloy, Sylvie Lachkar, Isabelle Martins, Paule Opolon, Andrea Checcoli, Agathe Delaune, Noémie Robil, Pierre de l
Journal of Experimental Medicine.2021;[Epub] CrossRef
Papillary Thyroid Cancer Prognosis: An Evolving Field
Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo, Flavio Forte, Alberto Santoro, Piergaspare Palumbo, Vito D’Andrea, Salvator
Cancers.2021; 13(21): 5567. CrossRef
Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables
Servet KOCAÖZ, Gülay TURAN
Düzce Tıp Fakültesi Dergisi.2021; 23(3): 252. CrossRef
Correlation Between Hashimoto's Thyroiditis–Related Thyroid Hormone Levels and 25-Hydroxyvitamin D
Guanqun Chao, Yue Zhu, Lizheng Fang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma
Dongbin Ahn, Gil J. Lee, Jin H. Sohn, Jae H. Jeon
Head & Neck.2020; 42(5): 1004. CrossRef
Suspicious ultrasound characteristics correlate with multiple factors that predict central lymph node metastasis of papillary thyroid carcinoma: Significant role of HBME-1
Li Jianming, Liu Jibin, Qian Linxue
European Journal of Radiology.2020; 123: 108801. CrossRef
Unexpected high‐risk pathologic features following thyroidectomy in the chinese immigrant population
Arvind K. Badhey, Erin Moshier, Ameya Jategaonkar, Anni Wong, Kristen Echanique, Raymond L. Chai
The Laryngoscope.2020; 130(7): 1844. CrossRef
Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links
Oksana Sulaieva, Oleksii Selezniov, Dmytro Shapochka, Nataliia Belemets, Oleksandr Nechay, Yelizaveta Chereshneva, Dibakhan Tsomartova, Marina Ivanova
Heliyon.2020; 6(1): e03077. CrossRef
Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto’s thyroiditis
Na Zhao, Xin Liu, Chao Wu, Yuanchao Liu, Xiangnan Zhao, Xianghui He
Journal of International Medical Research.2020;[Epub] CrossRef
Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis
Ohoud Subhi, Hans-Juergen Schulten, Nadia Bagatian, Roa'a Al-Dayini, Sajjad Karim, Sherin Bakhashab, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Mag
PLOS ONE.2020; 15(6): e0234566. CrossRef
Hashimoto's thyroiditis as a risk factor for thyroid cancer
Ulla Feldt-Rasmussen
Current Opinion in Endocrinology, Diabetes & Obesity.2020; 27(5): 364. CrossRef
Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Brafv600e Mutation: A Single Center Study of 1,207 Chinese Patients
Shuai Xue, Li Zhang, Peisong Wang, Jia Liu, Yue Yin, Meishan Jin, Liang Guo, Yuhua Zhou, Guang Chen
Frontiers in Endocrinology.2019;[Epub] CrossRef
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy
Francesca Ragusa, Poupak Fallahi, Giusy Elia, Debora Gonnella, Sabrina Rosaria Paparo, Claudia Giusti, Leonid P. Churilov, Silvia Martina Ferrari, Alessandro Antonelli
Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(6): 101367. CrossRef
Características anatomopatológicas del carcinoma papilar de tiroides en especimenes con y sin tiroiditis linfocitica crónica.
Carlos Osorio Covo, Jorge Ballestas Barrera, Jorge Martínez Castro, Zully Acevedo Meza, Diego Barrios Castellar, Francisco Herrera Sáenz, Cesar Redondo Bermúdez, Katherine Redondo De Oro
Revista Ciencias Biomédicas.2019; 8(2): 32. CrossRef

Thyroid
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea: Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung; Endocrinol Metab. 2018;33(2):287-295. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.287

11,224 View
96 Download
38 Web of Science
33 Crossref

Abstract PDF PubReader ePub

Background

Most patients with differentiated thyroid cancer (DTC) have a favorable prognosis. However, patients with DTC and initial distant metastasis have not been commonly found, and their clinical characteristics have seldom been reported. In this study, we analyzed the clinical features and prognosis of patients with DTC and initial distant metastasis in Korea.

Methods

We retrospectively reviewed the clinical data of 242 patients with DTC and initial distant metastasis treated from 1994 to 2013, collected from five tertiary hospitals in Korea.

Results

The patients' median age was 51 years, and 65% were women. They were followed for a median of 7 years. Lung was the most common site of distant metastasis: only lung 149 patients (62%), only bone 49 (20%), other single site one (pleura), and combined sites 43 (40 were lung and bone, two were bone and other site, and one was lung and other site). At the time of diagnosis, 50 patients (21%) had non-radioactive iodine (RAI) avidity. Five-year disease-specific survival (DSS) was 85% and 10-year DSS was 68%, which were better than those in previous studies. After multivariate analysis, old age, male sex, metastatic site, and histologic type (follicular type) were significant factors for poor prognosis. However, negative RAI avidity status was not a significant prognostic factor after adjusting for other variables.

Conclusion

The prognosis of Korean patients with DTC and initial distant metastasis was better than in previous studies. Old age, male sex, metastasis site, and histologic type were significant prognostic factors.

Citations

Citations to this article as recorded by

Characterizing thyroid carcinomas in the elderly: Histological subtypes and TERT promoter mutation analysis based on the latest WHO classification
Myoung Ju Koh, Songmi Noh, Jin Kyong Kim, Gi Jeong Kim
Annals of Diagnostic Pathology.2026; 80: 152578. CrossRef
A new therapeutic paradigm: radioiodine combined with lenvatinib for radioiodine-avid metastatic well-differentiated thyroid cancer
Siddharth Sharma, Aftab Hasan Nazar, Prabhakar Mishra, Manish Ora, Amitabh Arya, Sukanta Barai, Prasanta Kumar Pradhan, Sanjay Gambhir
Nuclear Medicine Communications.2025; 46(7): 605. CrossRef
Challenging diagnosis and treatment of rare paranasal sinus metastasis from thyroid cancer: a case report and literature review
Jee Hee Yoon, Ji Yong Park, A Ram Hong, Sung Sun Kim, Hee Kyung Kim, Ho-Cheol Kang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients With Bone Metastasis: Insights From a Population-Based Cohort Study
Hang Zhao, Xiao-Zhun Tang, Duo-Ping Wang, Peng-Cheng Yu, Cong He, Xu-Feng Chen, Wei-Dong Ye, Jia-Hao Wu, Jia-Qian Hu, Yu-Long Wang
Endocrine Practice.2025; 31(10): 1274. CrossRef
A Nomogram for Predicting Lung Metastasis in Papillary Thyroid Cancer Patients Aged Less Than 55 Years
Huiyun Yang, Qiuqin Qian, Yanling Li, Wenjie Pan, Jing Peng, Zhenyu Zou, Haiqing Zhu, Feng Shi
Frontiers in Endocrinology.2025;[Epub] CrossRef
Case report: A case of hyperthyroidism secondary to bone metastasis of differentiated thyroid cancer
Tingyu Gu, Zhihong Zhao, Yuanyuan Shi, Zhenhua Sun, Yao Wang, Zhiyuan He, Kun Wang
Frontiers in Oncology.2024;[Epub] CrossRef
Theranostics of Thyroid Cancer
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Armando De Virgilio, Petra Petranović Ovčariček
Seminars in Nuclear Medicine.2024; 54(4): 470. CrossRef
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček, Rainer Görges
Cancers.2023; 15(9): 2510. CrossRef
Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
Petra Petranović Ovčariček, Alfredo Campenni, Bart de Keizer, Desiree Deandreis, Michael C. Kreissl, Alexis Vrachimis, Murat Tuncel, Luca Giovanella
Cancers.2023; 15(17): 4290. CrossRef
Differentiating pulmonary metastasis from benign lung nodules in thyroid cancer patients using dual-energy CT parameters
Taeho Ha, Wooil Kim, Jaehyung Cha, Young Hen Lee, Hyung Suk Seo, So Young Park, Nan Hee Kim, Sung Ho Hwang, Hwan Seok Yong, Yu-Whan Oh, Eun-Young Kang, Cherry Kim
European Radiology.2022; 32(3): 1902. CrossRef
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal
Hsi-Chen Tsai, Kung-Chu Ho, Shih-Hsin Chen, Jing-Ren Tseng, Lan-Yan Yang, Kun-Ju Lin, Ju-Chin Cheng, Miaw-Jene Liou
Diagnostics.2022; 12(1): 221. CrossRef
Long-Term Quality of Life (5-15 Years Post-Thyroidectomy) of Thyroid Carcinoma Patients in Two Tertiary Care Hospitals
Mohammed Yousef Alyousef, Mohammed Khaled Ghandour, Mohammed Al-Mohawes, Mosaad Alnwaisir, Tahera Islam, Khalid Al Qahtani
Cureus.2022;[Epub] CrossRef
Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition
Pınar Celepli, İrem Bigat, Sefika Karabulut, Salih Celepli, Sema Hücümenoğlu
Annals of Diagnostic Pathology.2022; 59: 151973. CrossRef
Clinical study of ultrasonic evaluation of T/N staging of differentiated thyroid carcinoma using AJCC 8th staging criteria
Yu Liang, Xingxiang Huang, Zhe Song, Yang Yang, Ju Lei, Mei Ren, Li Tan, Hui Zhang, Francis Moore
PLOS ONE.2022; 17(6): e0269994. CrossRef
Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report
Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli, Elisabetta Micelli
World Journal of Obstetrics and Gynecology.2022; 11(3): 33. CrossRef
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Juan Antonio Vallejo Casas, Marcel Sambo, Carlos López López, Manuel Durán-Poveda, Julio Rodríguez-Villanueva García, Rita Joana Santos, Marta Llanos, Elena Navarro-González, Javier Aller, Virginia Pubul, Sonsoles Guadalix, Guillermo Crespo, Cintia Gonzál
European Thyroid Journal.2022;[Epub] CrossRef
Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
Scientific Reports.2021;[Epub] CrossRef
Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
Evert F S van Velsen, Merel T Stegenga, Folkert J van Kemenade, Boen L R Kam, Tessa M van Ginhoven, W Edward Visser, Robin P Peeters
The Journal of Clinical Endocrinology & Metabolism.2020; 105(3): e457. CrossRef
Usefulness of a 3D‐Printed Thyroid Cancer Phantom for Clinician to Patient Communication
Dayeong Hong, Sangwook Lee, Taehun Kim, Jung Hwan Baek, Won Woong Kim, Ki‐Wook Chung, Namkug Kim, Tae‐Yon Sung
World Journal of Surgery.2020; 44(3): 788. CrossRef
Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2020; 30(3): 418. CrossRef
Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
Alfredo Campennì, Daniele Barbaro, Marco Guzzo, Francesca Capoccetti, Luca Giovanella
Endocrine.2020; 70(2): 280. CrossRef
Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea
Jee Hee Yoon, Min Ji Jeon, Mijin Kim, A. Ram Hong, Hee Kyung Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Domenico Albano
PLOS ONE.2020; 15(8): e0238207. CrossRef
Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
Thyroid.2019; 29(12): 1804. CrossRef
Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
Xin-Yun Zhang, Jian-Wen Sun, Zhong-Ling Qiu, Yang Wang, Xiao-Yue Chen, Jin-Hua Zhao, Quan-Yong Luo
Endocrine.2019; 66(2): 254. CrossRef
Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis
Nilma Malik, Alyaksandr V. Nikitski, Elie Klam, Jason Hunt, Benjamin Witt, Barbara Chadwick, Yuri E. Nikiforov, Devaprabu Abraham
Endocrine Practice.2019; 25(12): 1255. CrossRef
Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
Scientific Reports.2019;[Epub] CrossRef
Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases
Anabela Zunino, Fabián Pitoia, Eduardo Faure, Adriana Reyes, Mónica Sala, Rosana Sklate, Verónica Ilera, Inés Califano
Endocrine.2019; 65(3): 630. CrossRef
The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study
Young Ki Lee, Daham Kim, Dong Yeob Shin, Cho Rok Lee, Eun Jig Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Annals of Surgical Oncology.2019; 26(7): 2200. CrossRef
Risk Factors for Distant Metastasis in Follicular Thyroid Carcinoma in Korea
Shin Dol Jo, Joon-Hyop Lee, Suk Ha Kang, Yun Yeong Kim, Yong Soon Chun, Heung Kyu Park, Sang Tae Choi, Jin Mo Kang, Yoo Seung Chung
Journal of Endocrine Surgery.2019; 19(1): 1. CrossRef
Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis
Houwei Zhu, Yanqing Qu
Oncology Letters.2019;[Epub] CrossRef
甲状腺腫瘍治療の最新情報

Nippon Jibiinkoka Gakkai Kaiho.2018; 121(11): 1336. CrossRef
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2018; 33(4): 459. CrossRef
Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
Frontiers in Oncology.2018;[Epub] CrossRef

Clinical Study
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease: Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(2):300-310. Published online April 25, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.300

9,067 View
117 Download
29 Web of Science
30 Crossref

Abstract PDF PubReader

Background

Hyperthyroidism relapse in Graves disease after antithyroid drug (ATD) withdrawal is common; however, measuring the thyrotropin receptor antibody (TRAb) at ATD withdrawal in order to predict outcomes is controversial. This study compared measurement of thyroid stimulatory antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) at ATD withdrawal to predict relapse.

Methods

This retrospective study enrolled patients with Graves disease who were treated with ATDs and whose serum thyroid-stimulating hormone levels were normal after receiving low-dose ATDs. ATD therapy was stopped irrespective of TRAb positivity after an additional 6 months of receiving the minimum dose of ATD therapy. Patients were followed using thyroid function tests and TSAb (TSAb group; n=35) or TBII (TBII group; n=39) every 3 to 6 months for 2 years after ATD withdrawal.

Results

Twenty-eight patients (38%) relapsed for a median follow-up of 21 months, and there were no differences in baseline clinical characteristics between groups. In the TSAb group, relapse was more common in patients with positive TSAb at ATD withdrawal (67%) than patients with negative TSAb (17%; P=0.007). Relapse-free survival was shorter in TSAb-positive patients. In the TBII group, there were no differences in the relapse rate and relapse-free survivals according to TBII positivity. For predicting Graves disease relapse, the sensitivity and specificity of TSAb were 63% and 83%, respectively, whereas those of TBII were 28% and 65%.

Conclusion

TSAb at ATD withdrawal can predict the relapse of Graves hyperthyroidism, but TBII cannot. Measuring TSAb at ATD withdrawal can assist with clinical decisions making for patients with Graves disease.

Citations

Citations to this article as recorded by

US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease
Mark A Lupo, Paul D Olivo, Maximilian Luffy, Jan Wolf, George J Kahaly
The Journal of Clinical Endocrinology & Metabolism.2025; 110(5): e1619. CrossRef
Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease
Rongguang Peng, Pu Xie, Zhou Jin, Wenzhong Zhou, Yanqiu Wang, Xinxin Chen, Qinglei Yin, Liyun Shen, Lingyang Meng, Lei Ye, Yulin Zhou, Shu Wang
The Journal of Clinical Endocrinology & Metabolism.2025; 110(9): e3002. CrossRef
Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves’ orbitopathy: a systematic review and meta-analysis
Abdulelah G. Abumohssin, Rayan A. Alshareef, Saja Aljohani, Abdulrahman Alqutub, Abdulsalam Alqutub
Eye.2025; 39(10): 1901. CrossRef
Analysis of Influencing Factors of Radioactive Iodine Therapy for Graves’ Disease
绍欣李
Journal of Clinical Personalized Medicine.2025; 04(03): 235. CrossRef
Thyrotropin (TSH)-Binding Inhibiting Immunoglobulin-Negative, Thyroid-Stimulating Antibody-Positive Amiodarone-Induced Thyrotoxicosis
Yasufumi Seki, Kei Inai, Koichiro Kaneko, Atsuhiro Ichihara
AACE Endocrinology and Diabetes.2025; 12(3): 190. CrossRef
Low-dose Methimazole in the Long-term Management of Graves' Disease: Small Doses, Big Benefits
Danilo Villagelin, David S Cooper
The Journal of Clinical Endocrinology & Metabolism.2025;[Epub] CrossRef
Thyroid-stimulating immunoglobulin levels during low-dose antithyroid therapy predict Graves’ disease relapse
Phong Vu Nhat Nguyen, Khue Thy Nguyen
Frontiers in Endocrinology.2025;[Epub] CrossRef
Thyroid stimulating receptor autoantibodies
Yumeng Gao, Ling Qiu, Songlin Yu, Xinqi Cheng
Clinica Chimica Acta.2024; 559: 119700. CrossRef
Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration
Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim
Endocrinology and Metabolism.2024; 39(4): 579. CrossRef
Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the diagnosis and management of Graves’ disease
Peiwei Yao, Yunliang Xie, Yunlin Wang, Chunyan Liang, Bingwen Huang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Analysis of Related Factors in Refractory Graves’ Disease
鑫王
Advances in Clinical Medicine.2023; 13(08): 13439. CrossRef
Interpretation of Thyroid Autoantibodies in Hyperthyroidism
Han-Sang Baek, Dong-Jun Lim
The Korean Journal of Medicine.2023; 98(3): 132. CrossRef
The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
Endocrinology and Metabolism.2023; 38(3): 338. CrossRef
Prediction of the recurrence risk of Graves' disease after antithyroid drug therapy
Qiang Zhang, Ying Fu
Environmental Disease.2023; 8(1): 7. CrossRef
Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse
Tiago Da Silva Santos, José Carlos Oliveira, Cláudia Freitas, André Couto de Carvalho
Cureus.2022;[Epub] CrossRef
The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
Journal of the Endocrine Society.2022;[Epub] CrossRef
Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy
Shiro Watanabe, Shozo Okamoto, Kazumasa Akikawa, Noriyuki Miyamoto, Miyuki Okamura-Kawasaki, Yuko Uchiyama, Junki Takenaka, Takuya Toyonaga, Kenji Hirata, Kohsuke Kudo
Annals of Nuclear Medicine.2022; 36(11): 923. CrossRef
The relationship between atherosclerotic disease and relapse during ATD treatment
Xinxin Zhu, Yaguang Zhang, Xiaoyu Zhao, Xiaona Zhang, Zixuan Ru, Yanmeizhi Wu, Xu Yang, Boyu Hou, Hong Qiao
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinology and Metabolism.2021; 36(3): 491. CrossRef
The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
Yulin Zhou, Mengxi Zhou, Yicheng Qi, Weiqing Wang, Xinxin Chen, Shu Wang
Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub] CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268. CrossRef
Graves' Disease: Can It Be Cured?
Wilmar M. Wiersinga
Endocrinology and Metabolism.2019; 34(1): 29. CrossRef
Medical Treatment of Graves' Disease
Hyun-Kyung Chung
International Journal of Thyroidology.2019; 12(2): 79. CrossRef
When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?
Suyeon Park, Eyun Song, Hye-Seon Oh, Mijin Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Doo Man Kim, Won Bae Kim
Endocrine.2019; 65(2): 348. CrossRef
Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse
Jianhui Li, Xiaohua Sun, Danzhen Yao, Jinying Xia
International Journal of Endocrinology.2018; 2018: 1. CrossRef
Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917. CrossRef
Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
Hoon Sung Choi, Won Sang Yoo
Endocrinology and Metabolism.2017; 32(2): 281. CrossRef
The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study
Ye An Kim, Sun Wook Cho, Hoon Sung Choi, Shinje Moon, Jae Hoon Moon, Kyung Won Kim, Do Joon Park, Ka Hee Yi, Young Joo Park, Bo Youn Cho
Thyroid.2017; 27(4): 491. CrossRef
The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
Myoung Sook Shim, Soo Min Nam, Jin Sae Yoo, Hae Kyung Kim, Sang Jun Lee, Mi Young Lee
International Journal of Thyroidology.2017; 10(2): 77. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef

Clinical Study
Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer: Sang Mi Kim, Eun Heui Kim, Bo Hyun Kim, Jong Ho Kim, Su Bin Park, Yoon Jeong Nam, Kang Hee Ahn, Min Young Oh, Won Jin Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Ju Kim; Endocrinol Metab. 2015;30(4):494-501. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.494

7,935 View
59 Download
49 Web of Science
46 Crossref

Abstract PDF PubReader

Background

Several inflammatory biomarkers, especially a high preoperative neutrophil-to-lymphocyte count ratio (NLR) and platelet-to-lymphocyte count ratio (PLR), are known to be indicator of poor prognosis in several cancers. However, very few studies have evaluated the significance of the NLR and PLR in papillary thyroid cancer (PTC). We evaluated the association of the preoperative NLR and PLR with clinicopathological characteristics in patients with PTC.

Methods

This study included 1,066 female patients who underwent total thyroidectomy for PTC. Patients were stratified into 4 quartiles by preoperative NLR and PLR. And the combination of preoperative NLR and PLR was calculated on the basis of data obtained value of tertile as follows: patients with both an elevated PLR and an elevated NLR were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively.

Results

The preoperative NLR and PLR were significantly lower in patients aged ≥45 years and in patients with Hashimoto's thyroiditis. The PLR was significantly higher in patients with tumor size >1 cm (P=0.021).When the patients were categorized into the aforementioned four groups, the group with the higher preoperative PLR was found to have a significantly increased incidence of lateral lymph node metastasis (LNM) (P=0.018). However, there are no significant association between the combination of preoperative NLR and PLR and prognostic factors in PTC patients.

Conclusion

These results suggest that a preoperative high PLR were significant associated with lateral LNM in female patients with PTC.

Citations

Citations to this article as recorded by

Are Inflammation Markers Derived from Hemogram Parameters Predictive for Papillary Thyroid Carcinoma in Hashimoto’s Thyroiditis Patients?
Can Akcura, Sedat Can Guney, Samet Alkan, Gamze Gelir Cavdar, Ayca Tan, Hasan Aydede, Zeliha Hekimsoy, Nilufer Ozdemir
Indian Journal of Surgery.2025; 87(6): 1053. CrossRef
Effect of Hemoglobin, Albumin, Lymphocyte Count, and Platelet (HALP) Score on Survival of Patients with Metastatic Thyroid Cancer Treated with Tyrosine Kinase Inhibitors
Hikmet Öztop, Fazıl Çağrı Hunutlu, Selin İldemir Ekizoğlu, Özen Öz Gül, Soner Cander, Ahmet Bilgehan Şahin
Journal of Clinical Medicine.2025; 14(4): 1306. CrossRef
Nomogram Model for Prognosis of Distant Metastatic DTC Based on Inflammatory and Clinicopathological Factors
Chenghui Lu, Guoqiang Wang, Zengmei Si, Fengqi Li, Xinfeng Liu, Na Han, Congcong Wang, Jiao Li, Xufu Wang
Journal of the Endocrine Society.2025;[Epub] CrossRef
Utility of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio as an Adjunct in Predicting Malignancy in Thyroid Nodules
Kul R Singh, Chanchal Rana, Anand Mishra, M Shreyamsa, Pooja Ramakant, V Sasi Mouli
World Journal of Endocrine Surgery.2025; 16(2): 27. CrossRef
Determination of the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases with Thyroid Nodules Detected by Bethesda 3 Cytology
Hasan Berk Şahin, Ugur Kesici, Ozben Yalcin, Seden Atike Arsoy Şahin, Mehmet Guray Duman, Orhan Yalcin
Indian Journal of Surgical Oncology.2025; 16(6): 1563. CrossRef
Correlation Between Preoperative Neutrophil-to-Lymphocyte Ratio and Clinicopathological Characteristics of Papillary Thyroid Carcinomas: Toward a Preoperative Biomarker
Chaima Ben Ammar, Makram Tbini, Ines Riahi, Mamia Ben Salah
Ear, Nose & Throat Journal.2025;[Epub] CrossRef
Single-cell perspective on the Monocyte-to-HDL cholesterol ratio as a metastasis biomarker in papillary thyroid cancer
Zhi-kun Ning, Hao Yi, Tingting Yang, Jiang Liu, Shanshan Su, Ting He, Haoyu Huang, Minghao Xie, Hui Li, Ying Tang, Xiaoping Zhu, Xiang Min
BMC Cancer.2025;[Epub] CrossRef
Correlation between preoperative uric acid levels and lymph node metastases in patients with papillary thyroid cancer: a retrospective study
ShaoKun Sun, Qin Zhou, Tao Hu
PeerJ.2025; 13: e19410. CrossRef
Clinical Value of Lymphocyte Count in Risk Prediction of Papillary Thyroid Carcinoma: A Case-Control Study in a Chinese Population
Xiu-Ping Qiu, Ru-Ying Xie, Yang Chen, Mei Tu, Ting Wang
Journal of Inflammation Research.2025; Volume 18: 12971. CrossRef
Evaluation of the correlation of neutrophil/lymphocyte ratio with prognostic classification systems in papillary thyroid carcinoma patients
Eren Ozan Yildiz, Kutay Işcen, Feyza Kaya, Onur Alptekin Güney, Suat Can Ulukent
Medicine.2024; 103(5): e37210. CrossRef
The Association of Pretreatment Systemic Immune Inflammatory Response Index (SII) and Neutrophil-to-Lymphocyte Ratio (NLR) with Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma
Yihua Gu, Ming Yu, Jiaqin Deng, Yeqian Lai
International Journal of General Medicine.2024; Volume 17: 2887. CrossRef
Prognostic nutritional index predicts lateral lymph node metastasis and recurrence free survival in papillary thyroid carcinoma
Junbin Zhang, Jinglin Gong, Hong Liu, Wenwen Zhou, Ming Cai, Chengyao Zhang
BMC Cancer.2024;[Epub] CrossRef
A Machine Learning-Based Model for Preoperative Assessment and Malignancy Prediction in Patients with Atypia of Undetermined Significance Thyroid Nodules
Gilseong Moon, Jae Hyun Park, Taesic Lee, Jong Ho Yoon
Journal of Clinical Medicine.2024; 13(24): 7769. CrossRef
Preoperative serum inflammation-based scores in medullary thyroid cancer
Ana Abrantes Figueiredo, Susana Esteves, Margarida Maria Moura, Pedro Marques, Joana Simões-Pereira, Valeriano Leite
Endocrinología, Diabetes y Nutrición.2023; 70(1): 48. CrossRef
Preoperative serum inflammation-based scores in medullary thyroid cancer
Ana Abrantes Figueiredo, Susana Esteves, Margarida Maria Moura, Pedro Marques, Joana Simões-Pereira, Valeriano Leite
Endocrinología, Diabetes y Nutrición (English ed.).2023; 70(1): 48. CrossRef
Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer: a systematic review and meta-analysis
Elena Russo, Mathilda Guizzardi, Luca Canali, Francesca Gaino, Andrea Costantino, Gherardo Mazziotti, Andrea Lania, Silvia Uccella, Luca Di Tommaso, Fabio Ferreli, Luca Malvezzi, Giuseppe Spriano, Giuseppe Mercante
Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1205. CrossRef
Association of Neutrophil-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio with Clinicopathological Features and Short-Term Outcome in Well-Differentiated Thyroid Cancer
Sumeet Suresh Malapure, Sibi Oommen, Shivanand Bhushan, Sucharitha Suresh, K. Devaraja
Indian Journal of Nuclear Medicine.2023; 38(4): 313. CrossRef
The predictive value of hematologic parameters in the risk of thyroid malignancy in cases with atypia/follicular lesion of undetermined significance
Hayri Bostan, Muhammed Erkam Sencar, Murat Calapkulu, Sema Hepsen, Pinar Akhanli, Hakan Duger, Bekir Ucan, Muhammed Kizilgul, Ilknur Ozturk Unsal, Mustafa Ozbek, Erman Cakal
European Archives of Oto-Rhino-Laryngology.2022; 279(8): 4077. CrossRef
Prognostic Impact of Inflammatory Markers PLR, LMR, PDW, MPV in Medullary Thyroid Carcinoma
Canxiao Li, Han Zhang, Shijie Li, Daqi Zhang, Jingting Li, Gianlorenzo Dionigi, Nan Liang, Hui Sun
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Role of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Diagnosing Thyroid Nodule
Haider Salim Mihson, Ayad Khani Maikhan, Ali Rodan Shuwelif
Mustansiriya Medical Journal.2022; 21(2): 155. CrossRef
Comparison of Mean Platelet Volume, Platelet Distribution Width, Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio and Lymphocyte/Monocyte Ratio in Patients with Differentiated Thyroid Cancer According to TSH Levels
Seher ÇETİNKAYA ALTUNTAŞ, Ömercan TOPALOĞLU
Batı Karadeniz Tıp Dergisi.2022; 6(3): 302. CrossRef
Delta Neutrophil Index and Neutrophil‐to‐Lymphocyte Ratio in the Differentiation of Thyroid Malignancy and Nodular Goiter
Mehmet Buğra Bozan, Fatih Mehmet Yazar, İlhami Taner Kale, Mehmet Fatih Yüzbaşıoğlu, Ömer Faruk Boran, Ayşe Azak Bozan
World Journal of Surgery.2021; 45(2): 507. CrossRef
Factors Affecting Central Node Metastasis and Metastatic Lymph Node Ratio in Papillary Thyroid Cancer
Jungirl Seok, Chang Hwan Ryu, Seog Yun Park, Chang Yoon Lee, Young Ki Lee, Yul Hwangbo, Eun Kyung Lee, You Jin Lee, Tae Sung Kim, Seok‐ki Kim, Yuh‐Seog Jung, Junsun Ryu
Otolaryngology–Head and Neck Surgery.2021; 165(4): 519. CrossRef
Neutrophil to iymphocyte ratio: Does it really differentiate between papillary thyroid carcinomas and multinodular goiter
Hakan BÖLÜKBAŞI, Serhan YILMAZ
Ege Tıp Dergisi.2021; 60(1): 63. CrossRef
Development and Validation of a Nomogram for Preoperative Prediction of Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma and Type 2 Diabetes Mellitus
Chao He, Yiqiao Lu, Binqi Wang, Jie He, Haiguang Liu, Xiaohua Zhang
Cancer Management and Research.2021; Volume 13: 2499. CrossRef
The diagnostic predictive value of neutrophil-to-lymphocyte ratio in thyroid cancer adjusted for tumor size
Taek Yoon Cheong, Sang Duk Hong, Keun-Woo Jung, Yoon Kyoung So, Paula Soares
PLOS ONE.2021; 16(5): e0251446. CrossRef
Usefulness of pre-thyroidectomy neutrophil–lymphocyte, platelet–lymphocyte, and monocyte–lymphocyte ratios for discriminating lymph node and distant metastases in differentiated thyroid cancer
Cínthia Minatel Riguetto, Icléia Siqueira Barreto, Frederico Fernandes Ribeiro Maia, Lígia Vera Montali da Assumpção, Denise Engelbrecht Zantut-Wittmann
Clinics.2021; 76: e3022. CrossRef
Serum Inflammation-based Scores in Endocrine Tumors
Pedro Marques, Friso de Vries, Olaf M Dekkers, Márta Korbonits, Nienke R Biermasz, Alberto M Pereira
The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e3796. CrossRef
Diferansiye Tiroid Kanserli Hastalarda Preoperatif Nötrofil / Lenfosit Oranının Boyun Ultrasonografisi ve Patolojik Bulgularla İlişkisi
Mehmet Esat DUYMUŞ
Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi.2021; 54(2): 243. CrossRef
Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer
Sorina Martin, Theodor Mustata, Oana Enache, Oana Ion, Andreea Chifulescu, Anca Sirbu, Carmen Barbu, Adrian Miron, Cosmin Giulea, Florin Andrei, Simona Fica
Diagnostics.2021; 11(11): 1959. CrossRef
The prognostic and diagnostic use of hematological parameters in subacute thyroiditis patients
Murat Calapkulu, Muhammed Erkam Sencar, Davut Sakiz, Hakan Duger, Ilknur Ozturk Unsal, Mustafa Ozbek, Erman Cakal
Endocrine.2020; 68(1): 138. CrossRef
Association of the Preoperative Inflammation-Based Scores with TNM Stage and Recurrence in Patients with Papillary Thyroid Carcinoma: A Retrospective, Multicenter Analysis

Wenjie Chen, Tao Wei, Zhihui Li, Rixiang Gong, Jianyong Lei, Jingqiang Zhu, Tao Huang
Cancer Management and Research.2020; Volume 12: 1809. CrossRef
Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma
Haruhiko Yamazaki, Kiminori Sugino, Kenichi Matsuzu, Chie Masaki, Junko Akaishi, Kiyomi Hames, Chisato Tomoda, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Munetaka Masuda, Koichi Ito
Endocrine.2020; 70(1): 115. CrossRef
Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment
Zhenyu Xie, Xin Li, Yuzhen He, Song Wu, Shiyue Wang, Jianjian Sun, Yuchen He, Yu Lun, Jian Zhang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Hipertiroidi Hastalarında Tedavi Öncesi ve Sonrası Trombosit/Lenfosit ve Nötrofil/Lenfosit Oranlarının Değerlendirilmesi
Çiğdem CİNDOĞLU, Mehmet GÜLER, Mehmet Ali EREN, Tevfik SABUNCU
Harran Üniversitesi Tıp Fakültesi Dergisi.2020; 17(1): 104. CrossRef
Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/ Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary Thyroid Carcinoma
Faruk Kutluturk, Serdar S. Gul, Safak Sahin, Turker Tasliyurt
Endocrine, Metabolic & Immune Disorders - Drug Targets.2019; 19(6): 859. CrossRef
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, Luca Modestino, Poupak Fallahi, Silvia Martina Ferrari, Amato de Paulis, Alessandro Antonelli, Maria Rosaria Galdiero
International Journal of Molecular Sciences.2019; 20(16): 3934. CrossRef
Different prognostic values of individual hematologic parameters in papillary thyroid cancer due to age-related changes in immunity
Kwan Ho Lee, Eun Young Seok, Eun Young Kim, Ji Sup Yun, Yong Lai Park, Chan Heun Park
Annals of Surgical Treatment and Research.2019; 96(2): 70. CrossRef
Diagnostic Accuracy of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Detecting Occult Papillary Thyroid Microcarcinomas in Benign Multinodular Goitres
Dimitrios K. Manatakis, Sophia Tseleni-Balafouta, Lazaros Tzelves, Dimitrios Balalis, Adelais Tzortzopoulou, Dimitrios P. Korkolis, George H. Sakorafas, Emmanouil Gontikakis, Georgios Plataniotis
Journal of Thyroid Research.2018; 2018: 1. CrossRef
Assessment of clinical and pathological features of patients who underwent thyroid surgery: A retrospective clinical study
Arif Emre, Sami Akbulut, Mehmet Sertkaya, Muharrem Bitiren, Ilhami Taner Kale, Ertan Bulbuloglu, Cemil Colak
World Journal of Clinical Cases.2018; 6(3): 20. CrossRef
Trends in white blood cell and platelet indices in a comparison of patients with papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions
Nikolaos Machairas, Ioannis D. Kostakis, Anastasia Prodromidou, Paraskevas Stamopoulos, Themistoklis Feretis, Zoe Garoufalia, Christos Damaskos, Gerasimos Tsourouflis, Gregory Kouraklis
Endocrine Research.2017; 42(4): 311. CrossRef
Evaluation of Hemocytometer Parameters as Potential Biomarkers in Benign Multinodular Goiter and Papillary Thyroid Carcinoma
Erdal Uysal, Seyit Mehmet Ceylan, Efe Sezgin, Hasan Bakir, Ahmet Orhan Gurer, Basar Aksoy, Mehmet Bastemir
Iranian Red Crescent Medical Journal.2017;[Epub] CrossRef
Clinical Value of Blood Neutrophil to Lymphocyte Ratio in Patients with Papillary Thyroid Carcinoma with Neck Lymph Node Metastasis
Hwa Bin Kim, Hyoung Shin Lee, Sung Won Kim, Seok Won Jeon, Ji Ah Song, Kang Dae Lee
International Journal of Thyroidology.2017; 10(2): 89. CrossRef
Association of Baseline Neutrophil-to-Lymphocyte Ratio with Clinicopathological Characteristics of Papillary Thyroid Carcinoma
Dimitrios K. Manatakis, Sofia Tseleni-Balafouta, Dimitrios Balalis, Vasiliki N. Soulou, Dimitrios P. Korkolis, George H. Sakorafas, Georgios Plataniotis, Emmanouil Gontikakis
International Journal of Endocrinology.2017; 2017: 1. CrossRef
Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma
Ke Jiang, Jianyong Lei, Wenjie Chen, Yanping Gong, Han Luo, Zhihui Li, Rixiang Gong, Jingqiang Zhu
Medicine.2016; 95(40): e5079. CrossRef
Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis
Ji-Feng Liu, Luo Ba, Hong Lv, Dan Lv, Jin-Tao Du, Xiao-Mei Jing, Ning-Jing Yang, Shao-Xin Wang, Chao Li, Xiao-Xia Li
Scientific Reports.2016;[Epub] CrossRef

Thyroid
The Frequency and Clinical Implications of the BRAF^V600E Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades: A Ram Hong, Jung Ah Lim, Tae Hyuk Kim, Hoon Sung Choi, Won Sang Yoo, Hye Sook Min, Jae Kyung Won, Kyu Eun Lee, Kyeong Cheon Jung, Do Joon Park, Young Joo Park; Endocrinol Metab. 2014;29(4):505-513. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.505

7,226 View
53 Download
52 Web of Science
44 Crossref

Abstract PDF PubReader

Background

Over the past several decades, there has been a rapid worldwide increase in the prevalence of papillary thyroid cancer (PTC) as well as a number of changes in the clinicopathological characteristics of this disease. BRAF^V600E, which is a mutation of the proto-oncogene BRAF, has become the most frequent genetic mutation associated with PTC, particularly in Korea. Thus, the present study investigated whether the prevalence of the BRAF^V600E mutation has increased over the past two decades in the Korean population and whether various PTC-related clinicopathological characteristics have changed.

Methods

The present study included 2,624 patients who underwent a thyroidectomy for PTC during two preselected periods; 1995 to 2003 and 2009 to 2012. The BRAF^V600E mutation status of each patient was confirmed using the polymerase chain reaction-restriction fragment length polymorphism method or by the direct sequencing of DNA.

Results

The prevalence of the BRAF^V600E mutation in Korean PTC patients increased from 62.2% to 73.7% (P=0.001) over the last two decades. Additionally, there was a greater degree of extrathyroidal extension (ETE) and lymph node metastasis in 2009 to 2012 patients with the BRAF^V600E mutation and a higher frequency of thyroiditis and follicular variant-PTC in 2009 to 2012 patients with wild-type BRAF. However, only the frequency of ETE was significantly higher in 1995 to 2003 patients with the BRAF^V600E mutation (P=0.047). Long-term recurrence rates during a 10-year median follow-up did not differ based on BRAF^V600E mutation status.

Conclusion

The BRAF^V600E mutation rate in Korean PTC patients has been persistently high (approximately 70%) over the past two decades and continues to increase. The present findings demonstrate that BRAF^V600E-positive PTC was associated with more aggressive clinicopathological features, especially in patients who were recently diagnosed, suggesting that BRAF^V600E mutation status may be a useful prognostic factor for PTC in patients recently diagnosed with this disease.

Citations

Citations to this article as recorded by

Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism
Vaishakhi Trivedi, Hitesh Kore, Disha Poojary, Vanita Noronha, Munita Bal, Pratik Chandrani, Anuradha Choughule, Priyanka Pange, Vinod Gupta, Nandini Menon, Vijay Patil, Minit Shah, Pankaj Chaturvedi, Kumar Prabhash, Amit Dutt
JCO Global Oncology.2025;[Epub] CrossRef
Prognostic Impact of Primary Tumor Size in Papillary Thyroid Carcinoma without Lymph Node Metastasis
Chae A Kim, Hye In Kim, Na Hyun Kim, Tae Yong Kim, Won Bae Kim, Jae Hoon Chung, Min Ji Jeon, Tae Hyuk Kim, Sun Wook Kim, Won Gu Kim
Endocrinology and Metabolism.2025; 40(3): 405. CrossRef
Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality
Elisa Gatta, Ilenia Pirola, Elena Gandossi, Virginia Maltese, Pietro Bellini, Riccardo Morandi, Davide Lombardi, Andrea Delbarba, Fiorella Marini, Claudio Casella, Francesco Bertagna, Carlo Cappelli
Endocrine Practice.2025;[Epub] CrossRef
Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study
Jiayu Huang, Jiazhi Wang, Jingchao Xv, Jingran Wang, Guangzhi Wang, Yongfu Zhao
Clinical and Experimental Medicine.2024;[Epub] CrossRef
The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant BRAF: A Systematic Review and Meta-Analysis
Sumathy Perampalam, Katherine Wu, Matti Gild, Lyndal Tacon, Martyn Bullock, Roderick Clifton-Bligh
Thyroid®.2024; 34(9): 1082. CrossRef
Association between Thyroid Profile Levels and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study
Yu-Shan Hsieh, Ting-Teng Yang, Chung-Huei Hsu, Yan-Yu Lin
Reports.2024; 7(3): 78. CrossRef
Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High BRAF Mutation Allele Frequency, Multiple Driver Gene Mutations, and RET Fusion May Indicate More Advanced TN Stage
Zhihong Wang, Peng Tang, Surong Hua, Junyi Gao, Bin Zhang, Hua Wan, Qixi Wu, Jiaxin Zhang, Ge Chen
OncoTargets and Therapy.2022; Volume 15: 147. CrossRef
Clinical significance of multi-genic assay in identifying aggressive papillary thyroid carcinoma
Lingfeng Tang, Xiujie Shu, Daixing Hu, Chang Deng, Haoyu Ren, Xinliang Su
American Journal of Otolaryngology.2022; 43(5): 103563. CrossRef
TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
Min Jhi Kim, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim, Kee-Hyun Nam
Cancers.2022; 14(19): 4928. CrossRef
Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study
Stéphane Bardet, Nicolas Goardon, Justine Lequesne, Dominique Vaur, Renaud Ciappuccini, Alexandra Leconte, Hervé Monpeyssen, Virginie Saguet-Rysanek, Bénédicte Clarisse, Audrey Lasne-Cardon, Fabrice Ménégaux, Laurence Leenhardt, Camille Buffet
Endocrine.2021; 71(2): 407. CrossRef
VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients
Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Sameer Aga
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Gene Mutation Analysis in Papillary Thyroid Carcinoma Using a Multi-Gene Panel in China
Qiang Wang, Ning Zhao, Jun Zhang
International Journal of General Medicine.2021; Volume 14: 5139. CrossRef
Null Association between BRAF V600E Mutation and Tumor Recurrence in Patients with Papillary Thyroid Microcarcinoma in South Korea
Ji Yoon Kim, Kyoung Jin Kim, Jae Hyun Bae, Joo Hyung Kim, Nam Hoon Kim, Hee Young Kim, Hoon Yub Kim, Seung-Kuk Baek, Sin Gon Kim, Kwang Yoon Jung, Kyeong Jin Kim
International Journal of Thyroidology.2021; 14(2): 135. CrossRef
Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?
Rania Makboul, Nadia M. Mostafa, Heba E.M. El-Deek, Noha A. Aboulhagag, Mahmoud R. Shehata, Yasser G. Abdelhafez
Nuclear Medicine Communications.2020; 41(5): 416. CrossRef
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Cancers.2020; 12(5): 1345. CrossRef
The clinical usefulness of chemokine C-X-C Motif Ligand 12 as a diagnostic marker for Papillary Thyroid Carcinoma
SangAh Lee, JaeHyuck Choi, SukJu Cho, JeeWon Chang, YoungHee Maeng
Indian Journal of Pathology and Microbiology.2020; 63(4): 544. CrossRef
Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC)
Sung Min Lee, Cho Rok Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Journal of Endocrine Surgery.2019; 19(3): 76. CrossRef
The role of Slit2 as a tumor suppressor in thyroid cancer
Min Ji Jeon, Seonhee Lim, Mi-hyeon You, Yangsoon Park, Dong Eun Song, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim
Molecular and Cellular Endocrinology.2019; 483: 87. CrossRef
BRAF mutation in papillary thyroid cancer—Prevalence and clinical correlation in a South‐East Asian cohort
Xueying Goh, Jeffery Lum, Samantha Peiling Yang, Siok Bee Chionh, Evelyn Koay, Lily Chiu, Rajeev Parameswaran, Kee Yuan Ngiam, Thomas Kwok Seng Loh, Min En Nga, Chwee Ming Lim
Clinical Otolaryngology.2019; 44(2): 114. CrossRef
Clinical Characteristics of Subtypes of Follicular Variant Papillary Thyroid Carcinoma
Min Joo Kim, Jae-Kyung Won, Kyeong Cheon Jung, Ji-hoon Kim, Sun Wook Cho, Do Joon Park, Young Joo Park
Thyroid.2018; 28(3): 311. CrossRef
Prevalence ofBRAFV600EMutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in aBRAFV600EPrevalent Area
Hyereen Kim, Bo Hyun Kim, Young Keum Kim, Jeong Mi Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Byung Joo Lee, Yong Ki Kim, In Joo Kim
Journal of Korean Medical Science.2018;[Epub] CrossRef
Case–Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea
Joon‐Hyop Lee, Ra‐Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su‐jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K. Park
World Journal of Surgery.2018; 42(5): 1424. CrossRef
Thyroid nodules with discordant results of ultrasonographic and fine-needle aspiration findings
Min Joo Kim, Ka Hee Yi
Journal of the Korean Medical Association.2018; 61(4): 225. CrossRef
Genetic landscape of papillary thyroid carcinoma in the Chinese population
Jialong Liang, Wanshi Cai, Dongdong Feng, Huajing Teng, Fengbiao Mao, Yi Jiang, Shanshan Hu, Xianfeng Li, Yujie Zhang, Baoguo Liu, Zhong Sheng Sun
The Journal of Pathology.2018; 244(2): 215. CrossRef
Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer
Young Shin Song, Jung Ah Lim, Hye Sook Min, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
European Journal of Endocrinology.2017; 177(6): 465. CrossRef
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
Cancer Research and Treatment.2017; 49(4): 906. CrossRef
Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature
A Krishnamurthy, V Ramshankar, K Murherkar, S Vidyarani, GC Raghunandhan, A Das, PB Desai, K Albert
Indian Journal of Cancer.2017; 54(1): 372. CrossRef
The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review
Huy Gia Vuong, Ahmed M.A. Altibi, Amr Hesham Abdelhamid, Phuong Uyen Duong Ngoc, Vo Duy Quan, Mohamed Yousef Tantawi, Mohamed Elfil, Tran Le Huy Vu, Ahmed Elgebaly, Naoki Oishi, Tadao Nakazawa, Kenji Hirayama, Ryohei Katoh, Nguyen Tien Huy, Tetsuo Kondo
Oncotarget.2017; 8(6): 10637. CrossRef
Current trends of practical issues concerning micropapillary thyroid carcinoma
Yoon Se Lee, Byung-Joo Lee, Hyun Joon Hong, Kang-Dae Lee
Medicine.2017; 96(45): e8596. CrossRef
Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy
Suyeon Park, Won Gu Kim, Eyun Song, Hye-Seon Oh, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(4): 524. CrossRef
Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
Chunping Liu, Tianwen Chen, Zeming Liu
World Journal of Surgical Oncology.2016;[Epub] CrossRef
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
Ja Seong Bae, Yourha Kim, Sora Jeon, Se Hee Kim, Tae Jung Kim, Sohee Lee, Min-Hee Kim, Dong Jun Lim, Youn Soo Lee, Chan Kwon Jung
Diagnostic Pathology.2016;[Epub] CrossRef
Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAFV600E Mutation-Prevalent Area
Min Ji Jeon, Sung-Min Chun, Deokhoon Kim, Hyemi Kwon, Eun Kyung Jang, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Se Jin Jang, Dong Eun Song, Won Gu Kim
Thyroid.2016; 26(5): 683. CrossRef
BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma
Brendon Mitchell, Jagdish K. Dhingra, Meera Mahalingam
Advances in Anatomic Pathology.2016; 23(4): 244. CrossRef
Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
Hyemi Kwon, Won Gu Kim, Markus Eszlinger, Ralf Paschke, Dong Eun Song, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(4): 586. CrossRef
Effect of Hashimoto thyroiditis on low‐dose radioactive‐iodine remnant ablation
Hyungju Kwon, June Young Choi, Jae Hoon Moon, Hyo Jin Park, Won Woo Lee, Kyu Eun Lee
Head & Neck.2016;[Epub] CrossRef
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(1): 100. CrossRef
Genetic alterations of differentiated thyroid carcinoma in iodine‐rich and iodine‐deficient countries
Huy Gia Vuong, Tetsuo Kondo, Naoki Oishi, Tadao Nakazawa, Kunio Mochizuki, Tomohiro Inoue, Ippei Tahara, Kazunari Kasai, Mitsuyoshi Hirokawa, Thong Minh Tran, Ryohei Katoh
Cancer Medicine.2016; 5(8): 1883. CrossRef
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae‐Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park, Jeong‐Sun Seo
Cancer.2016; 122(9): 1370. CrossRef
Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAFV600E Mutation–Prevalent Population
Seung Eun Lee, Tae Sook Hwang, Yoon-La Choi, Hye Seung Han, Wan Seop Kim, Min Hye Jang, Suk Kyeong Kim, Jung Hyun Yang
Thyroid.2016; 26(7): 901. CrossRef
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians
Young Shin Song, Jung Ah Lim, Young Joo Park
Endocrinology and Metabolism.2015; 30(3): 252. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Molecular Diagnosis for Cytologically Indeterminate Thyroid Nodules
Tae Sook Hwang
International Journal of Thyroidology.2015; 8(2): 153. CrossRef
Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma
Tae Yon Sung, Mijin Kim, Tae Yong Kim, Won Gu Kim, Yangsoon Park, Dong Eun Song, Su-Yeon Park, Hyemi Kwon, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Young Kee Shong, Suck Joon Hong, Won Bae Kim
Thyroid.2015; 25(9): 1020. CrossRef

Thyroid
Lack of Associations between Body Mass Index and Clinical Outcomes in Patients with Papillary Thyroid Carcinoma: Hyemi Kwon, Mijin Kim, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Suck Joon Hong, Won Bae Kim; Endocrinol Metab. 2015;30(3):305-311. Published online November 26, 2014; DOI: https://doi.org/10.3803/EnM.2015.30.3.305

6,993 View
44 Download
15 Web of Science
16 Crossref

Abstract PDF PubReader

Background

Obesity is associated with aggressive pathological features and poor clinical outcomes in breast and prostate cancers. In papillary thyroid carcinoma (PTC), these relationships remain still controversial. This study aimed to evaluate the associations between body mass index (BMI) and the clinical outcomes of patients with PTC.

Methods

This retrospective study included 1,189 patients who underwent total thyroidectomy for PTCs equal to or larger than 1 cm in size. Clinical outcomes were evaluated and compared based on the BMI quartiles.

Results

There were no significant associations between BMI quartiles and primary tumor size, extrathyroidal invasion, cervical lymph node metastasis, or distant metastasis. However, an increase in mean age was associated with an increased BMI (P for trend <0.001). Multifocality and advanced tumor-node-metastasis (TNM) stage (stage III or IV) were significantly associated with increases of BMI (P for trend 0.02 and <0.001, respectively). However, these associations of multifocality and advanced TNM stage with BMI were not significant in multivariate analyses adjusted for age and gender. Moreover, there were no differences in recurrence-free survivals according to BMI quartiles (P=0.26).

Conclusion

In the present study, BMI was not associated with the aggressive clinicopathological features or recurrence-free survivals in patients with PTC.

Citations

Citations to this article as recorded by

Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series
Alessandro Prete, Carla Gambale, Valeria Bottici, Virginia Cappagli, Giacomo Aringhieri, Marco Puccini, Stefano Landi, Liborio Torregrossa, Ferruccio Santini, Antonio Matrone, Rossella Elisei
Cancers.2025; 17(6): 950. CrossRef
The Role of Body Mass Index (BMI) in Differentiated Thyroid Cancer: A Potential Prognostic Factor?
Chiara Mele, Lucrezia De Marchi, Giulia Marsan, Marco Zavattaro, Maria Grazia Mauri, Paolo Aluffi Valletti, Gianluca Aimaretti, Paolo Marzullo
Biomedicines.2024; 12(9): 1962. CrossRef
A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study
Giorgio Grani, Michele Gentili, Federico Siciliano, Domenico Albano, Valentina Zilioli, Silvia Morelli, Efisio Puxeddu, Maria Chiara Zatelli, Irene Gagliardi, Alessandro Piovesan, Alice Nervo, Umberto Crocetti, Michela Massa, Maria Teresa Samà, Chiara Mel
The Journal of Clinical Endocrinology & Metabolism.2023; 108(8): 1921. CrossRef
Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study
Mijin Kim, Yae Eun Kang, Young Joo Park, Bon Seok Koo, Eu Jeong Ku, June Young Choi, Eun Kyung Lee, Bo Hyun Kim
Endocrine.2023; 82(1): 134. CrossRef
Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy
Jingjia Cao, Xiaolu Zhu, Yaru Sun, Xiao Li, Canhua Yun, Wei Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Nutritional status and follicular-derived thyroid cancer: An update
Luigi Barrea, Marco Gallo, Rosaria Maddalena Ruggeri, Paola Di Giacinto, Franz Sesti, Natalie Prinzi, Valerio Adinolfi, Viola Barucca, Valerio Renzelli, Giovanna Muscogiuri, Annamaria Colao, Roberto Baldelli
Critical Reviews in Food Science and Nutrition.2021; 61(1): 25. CrossRef
Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients
Onur Elbasan, Dilek Gogas Yavuz
Archives of Endocrinology and Metabolism.2021;[Epub] CrossRef
Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta‐Analysis
R. J. O'Neill, S. Abd Elwahab, M. J. Kerin, A. J. Lowery
World Journal of Surgery.2021; 45(9): 2805. CrossRef
Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis
Aliki Economides, Konstantinos Giannakou, Ioannis Mamais, Panayiotis A. Economides, Panagiotis Papageorgis
Frontiers in Endocrinology.2021;[Epub] CrossRef
Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer
Antonio Matrone, Giovanni Ceccarini, Marianna Beghini, Federica Ferrari, Carla Gambale, Mariaida D’Aqui, Paolo Piaggi, Liborio Torregrossa, Eleonora Molinaro, Fulvio Basolo, Paolo Vitti, Ferruccio Santini, Rossella Elisei
The Journal of Clinical Endocrinology & Metabolism.2020; 105(4): e1124. CrossRef
Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study
Huijuan Wang, Pingping Wang, Yu Wu, Xiukun Hou, Zechun Peng, Weiwei Yang, Lizhao Guan, Linfei Hu, Jingtai Zhi, Ming Gao, Xiangqian Zheng
PeerJ.2020; 8: e9675. CrossRef
Lack of association between obesity and aggressiveness of differentiated thyroid cancer
G. Grani, L. Lamartina, T. Montesano, G. Ronga, V. Maggisano, R. Falcone, V. Ramundo, L. Giacomelli, C. Durante, D. Russo, M. Maranghi
Journal of Endocrinological Investigation.2019; 42(1): 85. CrossRef
Mitochondrial DNA haplogroup K as a contributor to protection against thyroid cancer in a population from southeast Europe
Relu Cocoş, Sorina Schipor, Corin Badiu, Florina Raicu
Mitochondrion.2018; 39: 43. CrossRef
The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer
Danuta Gąsior-Perczak, Iwona Pałyga, Monika Szymonek, Artur Kowalik, Agnieszka Walczyk, Janusz Kopczyński, Katarzyna Lizis-Kolus, Tomasz Trybek, Estera Mikina, Dorota Szyska-Skrobot, Klaudia Gadawska-Juszczyk, Stefan Hurej, Artur Szczodry, Anna Słuszniak,
PLOS ONE.2018; 13(10): e0204668. CrossRef
Pretreatment BMI Is Associated with Aggressive Clinicopathological Features of Papillary Thyroid Carcinoma: A Multicenter Study
Shi-tong Yu, Wanzhi Chen, Qian Cai, Faya Liang, Debin Xu, Ping Han, Jichun Yu, Xiaoming Huang
International Journal of Endocrinology.2017; 2017: 1. CrossRef
Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer
Changhua Wu, Liang Wang, Wanjun Chen, Shujuan Zou, Aiju Yang
Medicine.2017; 96(9): e6202. CrossRef

Review Article

Thyroid
Current Status and Future Perspectives in Differentiated Thyroid Cancer: Tae Yong Kim, Won Gu Kim, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2014;29(3):217-225. Published online September 25, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.3.217

8,246 View
44 Download
79 Web of Science
66 Crossref

Abstract PDF PubReader

Thyroid cancer is increasing all over the world. The exact cause of this increase is still debated and there are conflicting reports. Sophisticated molecular studies suggest that environmental chemicals may have effects of thyroid carcinogenesis. The development of powerful molecular biology techniques has enabled targeted next-generation sequencing for detection of mutations in thyroid cancer, and this technique can make a specific diagnosis of thyroid cancer in cytologically indeterminate cases. The initial treatment of well-differentiated thyroid cancer (DTC) is surgery followed by radioiodine remnant ablation. However, further studies are needed to determine the optimal dosage of radioactive iodine for DTC patients with lateral neck metastasis. DTC is an indolent tumor and may cause death even decades later. Thus, long-term follow-up is mandatory. Recently, dynamic risk stratification (DRS) has begun to use stimulated thyroglobulin level at 1 year after the initial treatment and restratified the risk in accordance with the response to the initial treatment. This DRS strategy accurately predicts disease free survival and can be widely used in daily clinical settings. For the iodine refractory metastatic disease, redifferentiation therapy and targeted therapy are two promising alternative treatments. Sorafenib is the first approved agent for the treatment of progressive iodine refractory advanced thyroid cancer in Korea and may be very helpful for radioactive-refractory locally advanced or metastatic DTC. Selumetinib may be an effective redifferentiating agent and could be used within several years.

Citations

Citations to this article as recorded by

Locoregional Recurrence after Biochemical Incomplete Response in Differentiated Thyroid Cancer Patients: Insights into Influencing Clinicopathological Factors and the Potential Role of 18F-FDG PET/CT
Mai Amr Elahmadawy, Ismail Mohamed Ali, Ibrahim Mansour Nasr, Omnia Talaat
World Journal of Nuclear Medicine.2025;[Epub] CrossRef
Association between metabolic dysfunction-associated steatotic liver disease and the risk of thyroid cancer: a nationwide cohort study
Jeongmin Lee, Jeongeun Kwak, Min-Hee Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Hun-Sung Kim
The Korean Journal of Internal Medicine.2025; 40(5): 813. CrossRef
Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea
Hyemi Kwon, Kyung-Do Han, Sun Joon Moon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1095. CrossRef
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
Hélène Lasolle, Andrea Schiavo, Adrien Tourneur, Pierre Gillotay, Bárbara de Faria da Fonseca, Lucieli Ceolin, Olivier Monestier, Benilda Aganahi, Laura Chomette, Marina Malta Letro Kizys, Lieven Haenebalcke, Tim Pieters, Steven Goossens, Jody Haigh, Vinc
Oncogene.2024; 43(3): 155. CrossRef
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation
Jing-Yang Su
American Journal of Cancer Research.2024; 14(2): 407. CrossRef
F-18 FDG PET/CT Versus RAI-WBS and Neck USG in Early Diagnosis of Recurrent Differentiated Thyroid Cancer
Jaimanti Bakshi, Naresh K. Panda, Atul Kumar Goyal, Jyoti Saini, Sovit Jung Baral, Bhagwant Rai Mittal, Anupam Lal
Journal of Pharmaceutical and BioSciences.2024; 12(3): 9. CrossRef
Study on Impact of Interpolation Methods on Performance of Super-Resolution ResNet Model in Nuclear Medicine Thyroid Phantom Imaging
Minha Kim, Chanrok Park
Journal of Radiological Science and Technology.2024; 47(6): 433. CrossRef
Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer
Tairong Liang, Xiuqian Wu, Lan Wang, Zhengzhong Ni, Ying Fan, Peishan Wu, Hongzhi Wang, Yongdong Niu, Haihua Huang
Pathology - Research and Practice.2023; 245: 154431. CrossRef
Thyroidkeeper: a healthcare management system for patients with thyroid diseases
Jing Zhang, Jianhua Li, Yi Zhu, Yu Fu, Lixia Chen
Health Information Science and Systems.2023;[Epub] CrossRef
Repeated Low High-Density Lipoprotein Cholesterol and the Risk of Thyroid Cancer: A Nationwide Population- Based Study in Korea
Jinyoung Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Kyungdo Han, Hyuk-Sang Kwon
Endocrinology and Metabolism.2022; 37(2): 303. CrossRef
Comparison of the prognostic value of AJCC cancer staging system 7th and 8th editions for differentiated thyroid cancer
Y. J. Morosán Allo, L. Bosio, A. Morejón, C. Parisi, M. C. Faingold, V. Ilera, A. Gauna, G. Brenta
BMC Endocrine Disorders.2022;[Epub] CrossRef
Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry
Jonghwa Ahn, Meihua Jin, Eyun Song, Yeon-mi Ryu, Dong Eun Song, Sang-Yeob Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
Thyroid.2021; 31(1): 61. CrossRef
A double mutation of BRAF L597Q and V600E in situ and solitary brain metastasis of occult papillary thyroid carcinoma
Ling Chen, Yue Wu, Huili Bai, Huandong Liu, Xiaosong Li
Medicine.2021; 100(6): e24458. CrossRef
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma
Eyun Song, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong, Won Gu Kim
Cancers.2021; 13(22): 5846. CrossRef
Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
Young Kee Shong
International Journal of Thyroidology.2021; 14(2): 98. CrossRef
Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma
Yan Dong, Dan Wang, Yisheng Luo, Ling Chen, Huili Bai, Yifan Shen, Yangli Zhang, Xueping Chen, Xinliang Su, Jinqiu Zhao, Huandong Liu, Jungao Lu, Zuoyi Yao, Yajing Zhao, Changlong He, Xiaosong Li
Oncology Letters.2021;[Epub] CrossRef
Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea
Eyun Song, Mijin Kim, Eui Young Kim, Bo Hyun Kim, Dong Yeob Shin, Ho-Cheol Kang, Byeong-Cheol Ahn, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Dong Jun Lim
Thyroid.2020; 30(5): 732. CrossRef
Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation
Yeon-Hee Han, Hwan-Jeong Jeong, Myung-Hee Sohn, Sun Y. Lee, Seok T. Lim
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub] CrossRef
Metabolic Syndrome and the Risk of Thyroid Cancer: A Nationwide Population-Based Cohort Study
Joo-Hyun Park, Moonyoung Choi, Jung-Hun Kim, Jaemin Kim, Kyungdo Han, Bongsung Kim, Do-Hoon Kim, Yong-Gyu Park
Thyroid.2020; 30(10): 1496. CrossRef
Serum Adiponectin and Progranulin Level in Patients with Benign Thyroid Nodule or Papillary Thyroid Cancer
Hyemi Kwon, Se Eun Park, Ji-Sup Yun, Cheol-Young Park
Endocrinology and Metabolism.2020; 35(2): 396. CrossRef
The role of Slit2 as a tumor suppressor in thyroid cancer
Min Ji Jeon, Seonhee Lim, Mi-hyeon You, Yangsoon Park, Dong Eun Song, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim
Molecular and Cellular Endocrinology.2019; 483: 87. CrossRef
Metabolic Obesity Phenotypes and Thyroid Cancer Risk: A Cohort Study
Hyemi Kwon, Yoosoo Chang, Ara Cho, Jiin Ahn, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Hocheol Shin, Seungho Ryu, Eun-Jung Rhee
Thyroid.2019; 29(3): 349. CrossRef
Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Clinical Endocrinology.2019; 91(3): 449. CrossRef
Myxedema coma precipitated by diabetic ketoacidosis after total thyroidectomy: a case report
Jin Joo Kim, Eun Young Kim
Journal of Medical Case Reports.2019;[Epub] CrossRef
Comprehensive analysis for diagnosis of preoperative non-invasive follicular thyroid neoplasm with papillary-like nuclear features
Hye Seung Lee, Jae-Wook Lee, Ji Hyun Park, Wan-Seop Kim, Hye Seung Han, Seung Eun Lee, Paula Soares
PLOS ONE.2019; 14(7): e0218046. CrossRef
Rutin Scavenges Reactive Oxygen Species, Inactivates 5′-Adenosine Monophosphate-Activated Protein Kinase, and Increases Sodium–Iodide Symporter Expression in Thyroid PCCL3 Cells
Carlos Frederico Lima Gonçalves, Mariana Lopes de Freitas, Rodrigo Soares Fortunato, Leandro Miranda-Alves, Denise P. Carvalho, Andrea Claudia Freitas Ferreira
Thyroid.2018; 28(2): 265. CrossRef
Prevalence ofBRAFV600EMutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in aBRAFV600EPrevalent Area
Hyereen Kim, Bo Hyun Kim, Young Keum Kim, Jeong Mi Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Byung Joo Lee, Yong Ki Kim, In Joo Kim
Journal of Korean Medical Science.2018;[Epub] CrossRef
Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer
Neeta J. Erinjeri, Norman G. Nicolson, Christine Deyholos, Reju Korah, Tobias Carling
Journal of the American College of Surgeons.2018; 226(6): 950. CrossRef
Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
Frontiers in Oncology.2018;[Epub] CrossRef
Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Eyun Song, Min Ji Jeon, Hye-Seon Oh, Minkyu Han, Yu-Mi Lee, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Dong Eun Song, Won Gu Kim
European Journal of Endocrinology.2018; 179(3): 135. CrossRef
SPC24 is critical for anaplastic thyroid cancer progression
Huabin Yin, Tong Meng, Lei Zhou, Haiyan Chen, Dianwen Song
Oncotarget.2017; 8(13): 21884. CrossRef
Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis
Renfei Wang, Yueqian Zhang, Jian Tan, Guizhi Zhang, Ruiguo Zhang, Wei Zheng, Yajing He
Medicine.2017; 96(19): e6809. CrossRef
Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication
Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jae Hoon Chung, Seong Mi Moon, Byung Woo Jhun, Hyun Lee, Won-Jung Koh, Sun Wook Kim, Dongmei Li
PLOS ONE.2017; 12(1): e0169775. CrossRef
DelayedTSHrecovery after dose adjustment duringTSH‐suppressive levothyroxine therapy of thyroid cancer
Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jung‐Han Kim, Kyu Yeon Hur, Jae Hoon Chung, Sun Wook Kim
Clinical Endocrinology.2017; 87(3): 286. CrossRef
Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease
Yun Mi Choi, Won Gu Kim, Tae Yong Kim, Sung Jin Bae, Hong-Kyu Kim, Eun Kyung Jang, Min Ji Jeon, Ji Min Han, Young Kee Shong, Won Bae Kim
The Korean Journal of Internal Medicine.2017; 32(1): 102. CrossRef
Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
Mijin Kim, Young Nam Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Hyeon Seon Ahn, Sin-Ho Jung, Sun Wook Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Tae Hyuk Kim, Tae Yong Kim
Clinical Endocrinology.2017; 86(3): 438. CrossRef
Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung
Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(1): 49. CrossRef
Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations
Tae Hyuk Kim, Chang-Seok Ki, Hye Seung Kim, Kyunga Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hye Won Jang, Sun Wook Kim, Jae Hoon Chung
The Journal of Clinical Endocrinology & Metabolism.2017; 102(5): 1757. CrossRef
Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer
Mijin Kim, Won Gu Kim, Hye-Seon Oh, Suyeon Park, Hyemi Kwon, Dong Eun Song, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Tae-Yon Sung, Min Ji Jeon
Thyroid.2017; 27(9): 1149. CrossRef
Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma
Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(7): 915. CrossRef
Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas
Hyemi Kwon, Min Ji Jeon, Jong Ho Yoon, Suck Joon Hong, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
Journal of Surgical Oncology.2017; 116(6): 746. CrossRef
Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
Douglas Van Nostrand
Journal of Nuclear Medicine.2017; 58(5): 697. CrossRef
Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy
Xingchen Shang, Xia Zhong, Xingsong Tian
Tumor Biology.2016; 37(8): 11163. CrossRef
Recent Updates on the Management of Medullary Thyroid Carcinoma
Bo Hyun Kim, In Joo Kim
Endocrinology and Metabolism.2016; 31(3): 392. CrossRef
Intraoperative Near‐infrared Imaging for Parathyroid Gland Identification by Auto‐fluorescence: A Feasibility Study
Frederic De Leeuw, Ingrid Breuskin, Muriel Abbaci, Odile Casiraghi, Haïtham Mirghani, Aïcha Ben Lakhdar, Corinne Laplace‐Builhé, Dana Hartl
World Journal of Surgery.2016; 40(9): 2131. CrossRef
Papillary thyroid carcinoma: different clinical behavior among pT3 tumors
Maria Joana Santos, Maria João Bugalho
Endocrine.2016; 53(3): 754. CrossRef
Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Journal of Surgical Oncology.2016; 113(2): 152. CrossRef
Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography
BIN LONG, MENGDI YANG, ZHIWEN YANG, HEQING YI, LINFA LI
Oncology Letters.2016; 11(2): 965. CrossRef
Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma
CUN-ZHI LU, SU-SHENG CAO, WEI WANG, JUN LIU, NING FU, FENG LU
Oncology Letters.2016; 11(4): 2420. CrossRef
Coexistence of papillary thyroid microcarcinoma and mucosa-associated lymphoid tissue lymphoma in a context of Hashimoto's thyroiditis
Saul Levy-Blitchtein, Stefany Plasencia-Rebata, Domingo Morales Luna, Juana del Valle Mendoza
Asian Pacific Journal of Tropical Medicine.2016; 9(8): 812. CrossRef
Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know
Mohammad Javed Ali
Ophthalmic Plastic & Reconstructive Surgery.2016; 32(4): 243. CrossRef
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(1): 100. CrossRef
Dietary evaluation of a low-iodine diet in Korean thyroid cancer patients preparing for radioactive iodine therapy in an iodine-rich region
Dal Lae Ju, Young Joo Park, Hee-Young Paik, Min-Ji Kim, Seonyeong Park, Kyong Yeun Jung, Tae Hyuk Kim, Hun Sung Choi, Yoon Ju Song
Nutrition Research and Practice.2016; 10(2): 167. CrossRef
Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Tae Yong Kim, Young Kee Shong, Dong Eun Song, Won Bae Kim
Thyroid.2016; 26(1): 161. CrossRef
Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
Min Ji Jeon, Won Gu Kim, Seonhee Lim, Hyun-Jeung Choi, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Molecular and Cellular Endocrinology.2016; 419: 113. CrossRef
Differentiated Thyroid Cancer in Asians
Bo Hyun Kim
Endocrinology and Metabolism.2016; 31(1): 62. CrossRef
Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria
Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jin-Sook Ryu, Ji Min Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Konradin Metze
PLOS ONE.2015; 10(7): e0133625. CrossRef
The Impact of Low Adherence to the Low-iodine Diet on the Efficacy of the Radioactive Iodine Ablation Therapy
Dal Lae Ju, Young Joo Park, Hee-Young Paik, YoonJu Song
Clinical Nutrition Research.2015; 4(4): 267. CrossRef
High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma
Bo Hyun Kim, Seong-Jang Kim, Keunyoung Kim, Heeyoung Kim, So Jung Kim, Won Jin Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Joo Kim
Annals of Nuclear Medicine.2015; 29(8): 721. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Changes in the Pulmonary Function Test after Radioactive Iodine Treatment in Patients with Pulmonary Metastases of Differentiated Thyroid Cancer
Eun Kyung Jang, Won Gu Kim, Ho-Cheol Kim, Jin-Won Huh, Hyemi Kwon, Yun Mi Choi, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Jin-Sook Ryu, Won Bae Kim, Karen M. Tordjman
PLOS ONE.2015; 10(4): e0125114. CrossRef
Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma
Tae Yon Sung, Mijin Kim, Tae Yong Kim, Won Gu Kim, Yangsoon Park, Dong Eun Song, Su-Yeon Park, Hyemi Kwon, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Young Kee Shong, Suck Joon Hong, Won Bae Kim
Thyroid.2015; 25(9): 1020. CrossRef
Thyroglobulin Level in Fine-Needle Aspirates for Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma: Two Different Cutoff Values According to Serum Thyroglobulin Level
Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2015; 25(4): 410. CrossRef
A Closer Look at Papillary Thyroid Carcinoma
Won Bae Kim
Endocrinology and Metabolism.2015; 30(1): 1. CrossRef
Protecting the normal in order to better kill the cancer
Bingya Liu, Lewis Ezeogu, Lucas Zellmer, Baofa Yu, Ningzhi Xu, Dezhong Joshua Liao
Cancer Medicine.2015; 4(9): 1394. CrossRef
Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470. CrossRef

Case Report

Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma.: Min Ji Jeon, Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2011;26(4):330-334. Published online December 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.4.330

41,671 View
38 Download
3 Crossref

Abstract PDF

Papillary thyroid carcinoma could be a rare cause of malignant pleural effusion. The development of malignant pleural effusion in patients with papillary thyroid cancer is an extremely adverse prognostic indicator. Here, we report four cases that showed development of malignant pleural effusion during the clinical course of the papillary thyroid carcinoma and consider the prognosis. In four patients, the median survival time after the development of malignant pleural effusion was only 17 months.

Citations

Citations to this article as recorded by

Pleural fluid due to papillary thyroid cancer
Tomohiro Tamura, Toshihiro Shiozawa, Hiroaki Satoh, Koichi Kurishima, Katsunori Kagohashi, Norio Takayashiki, Nobuyuki Hizawa
Oncology Letters.2019;[Epub] CrossRef
Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma
Chisato Tomoda, Yuna Ogimi, Fumi Saito, Chie Masaki, Junko Akaishi, Kenichi Matsuzu, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Hiroshi Shibuya, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Koichi Ito
Endocrine Journal.2016; 63(3): 257. CrossRef
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report
Andrew Rosenstengel, Ee Mun Lim, Michael Millward, YC Gary Lee
Journal of Medical Case Reports.2013;[Epub] CrossRef

Original Articles

Expression of miRNA 146a/b, 221 and 222 in Thyroid Cancer.: Young Suk Jo, Ihn Suk Lee, Woojeong Hong, In Sang Song, Minho Shong, Je Ryoung Kim; J Korean Endocr Soc. 2009;24(1):17-24. Published online March 1, 2009; DOI: https://doi.org/10.3803/jkes.2009.24.1.17

2,677 View
23 Download
1 Crossref

Abstract PDF

BACKGROUND
miRNAs can be diagnostic markers and therapeutic targets in cancers, but few studies have been conducted in thyroid cancer. We investigated the expression levels of miRNA 146a/b, 221, and 222 which are important miRNAs in papillary thyroid cancers (PTCa), and verified their impact on clinicopathological factors. METHODS: We measured the expression of pre-miRNAs 146a/b, 221, and 222 in NPA cells treated with 10% fetal bovine serum (FBS) or in HEK293T cells transfected with RET/PTC3 or BRAFV600E expression vectors. We also investigated the relationship between miRNA expression levels in thyroid cancer tissue specimens and clinicopathological parameters. RESULTS: Growth stimulation with 10% FBS induced miRNA expressions in NPA cells, and transfection of RET/PTC3 and BRAFV600E also increased the expression of these miRNAs in HEK293T cells. Most (25 cases; 50%) of PTCa showed increased expression of miRNA-146a/b and 30 cases (60%) had elevated expression of miRNA-221 and miRNA-222 compared to normal thyroid samples from the contralateral lobe. However, increased miRNA expression did not correlate with clinicopathological factors. CONCLUSION: Expression of miRNA 146a/b, 221, and 222 was increased by BRAFV600E and RET/PTC3 rearrangement and might have a role in tumorigenesis in PTCa. However, expression levels of these miRNAs did not correlate with clinicopathological parameters of patients with PTCa.

Citations

Citations to this article as recorded by

Expression of miRNA 146a/b, 221 and 222 in Thyroid Cancer
Do Joon Park
Journal of Korean Endocrine Society.2009; 24(1): 15. CrossRef

Clinical Characteristics of Poorly Differentiated Carcinoma of the Thyroid and Comparison of Its Survival to the Tall Cell and Columnar Cell Variants of Papillary Carcinoma.: Tae Sik Jung, Jae Hoon Chung, Young Lyun Oh, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Kyung Won Kim, Young Joo Park, Bo Youn Cho; J Korean Endocr Soc. 2006;21(2):132-141. Published online April 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.2.132

2,617 View
29 Download

Abstract PDF: BACKGROUND
Poorly differentiated carcinoma (PDC) of the thyroid includes tall and columnar cell variants (TCV) of the papillary carcinoma as well as the thyroid carcinoma with trabecular, insular and solid (TIS) growth patterns. There have been a few clinical studies on the PDC of the thyroid. We evaluated the clinical characteristics and the outcome of the PDC. METHODS: We investigated the clinicopathologic features of the thyroid carcinoma with TIS growth patterns (n = 46) and TCV of the papillary carcinoma (n = 14). We investigated the clinical features of ten patients diagnosed as PDC of the thyroid who had been undergone thyroidectomy for well differentiated carcinoma previously and compared these outcome with those of patients primarily diagnosed as PDC of the thyroid (n = 60). RESULTS: The clinical course of the thyroid carcinoma with TIS growth patterns was slightly more aggressive than that of TCV of the papillary carcinoma. However, disease-specific survivals of both cancers were not significantly different. Disease-specific survival was independently correlated with the presence of distant metastasis at diagnosis and high dose radioiodine therapy. The clinical features and outcome of the patients with PDC detected at recurred sites after operation for well-differentiated carcinoma were more aggressive than those diagnosed as PDC of the thyroid. CONCLUSION: The prognosis of the thyroid carcinoma with TIS growth patterns and TCV of the papillary carcinoma were similar. The PDC which was detected after thyroidectomy for well-differentiated carcinoma had worse prognosis than primarily diagnosed as PDC of the thyroid.

First
Prev
Page of 1
Next
Last

Search